European Journal of Cancer

Rectal cancer treatment in the next century
pp. 1-1(1)
Author: Pahlman L.

Genetic developments and nursing practice: the future is closer than you think!
pp. 5-5(1)
Author: Batchelor D.

Information technology and cancer nursing: how to combine technology and touch
pp. 6-6(1)
Author: Sermeus W.

Developing European standards of nursing care
pp. 7-7(1)
Authors: Miller M.; Kearney N.

Post-graduate cancer nursing education. From inservice to certification
pp. 7-7(1)
Authors: Smadar N.; Yaffe A.

Nursing problems in surgical oncology, can we predict them?
pp. 7-7(1)
Authors: de Kruif J.T.C.M.; van den Berg H.B.

A new treatment for the head and neck cancer patient. Radplat: a nursing challenge!
pp. 7-7(1)
Author: Visser J.C.

Integrating in- and out-patient nursing services for breast cancer patients undergoing mastectomy and breast conserving surgery
pp. 8-8(1)
Author: van Wijngaarden M.G.

Nurse's counselling role in cancer
pp. 8-8(1)
Author: Ferrario R.

The use of a telephone triage (TT) for an out of hours service in transmural palliative care
pp. 8-8(1)
Authors: Elfrink E.J.; Elswijk P.; van der Rijt C.C.D.

The crisis of sudden death: an unmet need in cancer care?
pp. 8-8(1)
Author: Porter H.

Representative information on side-effects of chemotherapy
pp. 8-9(2)
Author: Heijer A.D.-d.

The 'Chemo-Quiz', a creative way to learn
pp. 9-9(1)
Authors: de Ruijter W.; Eeltink C.M.

''Plastic surgery over-then what?'' The development of a network to help patients cope with altered body image and self concept following surgery
pp. 9-9(1)
Authors: Burton A.; Cunningham T.; Plaiter T.

Trained professionals as a resourse in canser care and treatment. A co-operative model for professional development and continuity in the public health system
pp. 9-9(1)
Author: Kolsvik E.

Community palliative care needs assessment
pp. 9-9(1)
Author: Garland E.

Backbone for research nurses within the new drug development team: improving efficiency and communication
pp. 9-10(2)
Author: van Wijk A.W.

Regular counselling by an oncology nurse increases coping with side effects during outpatients radiotherapy of gynecological malignancies
pp. 10-10(1)
Authors: Varre P.; Jacobsen A.M.; Flovik A.M.; Skovlund E.; Fossa S.D.

How important is the role of the research nurse in the care of patients entered into cancer clinical trials?
pp. 10-10(1)
Authors: Varcoe S.M.; Elliott M.E.

Group protocol for the administration of adjuvant chemotherapy using, cyclophosphamide, methorexate, and 5fluorouracil (C.M.F.) to patients with breast cancer, by nurses within an out-patient setting
pp. 10-10(1)
Author: Ryan D.

An exploratory study examining patients' perceptions of rehabilitation following bowel cancer
pp. 10-10(1)
Author: Howard-Jones G.

Continuous nurse education: improving cancer care through education for nurses
pp. 10-11(2)
Author: Laze I.

Using the audit cyccle to change practice: developing an holistic approach to delivery of chemotherapy
pp. 11-11(1)
Author: Richardson H.

Organisation of chemotherapy services and patient care in adepartment of medical oncology of a comprehensive cancer centre: role of a nurse in transitional period of the society
pp. 11-11(1)
Author: Kocanova J.

Hospice at Home: a 2 year pilot project providing specialist palliative care at home
pp. 11-11(1)
Authors: Graham J.; McGill M.; Munroe S.

Preceptorship package: finding your way in a new specialty
pp. 11-11(1)
Authors: Prince A.; Shrewbridge A.; Cathmoir D.

Cancer patients seeking information from sources outside the health care system
pp. 11-12(2)
Author: Carlsson M.

A strategy for advancing practice; paediatric oncology nursing
pp. 12-12(1)
Author: Gibson F.

The role of the specialist oncology nurse practitioner in delivering accelerated, dose-intensive chemotherapy with autologous, progenitor cell-enriched whole blood re-infusion
pp. 12-12(1)
Author: Diffley J.

Altered body image following adolescent bone cancer
pp. 12-12(1)
Author: Nendick M.E.

Everyday coping of adolesecents with cancer
pp. 12-12(1)
Authors: Seppanen P.; Jamsa T.; Mikkonen R.; Nousiainen E.-M.; Rytilahti M.; Vattovaara R.; Kyngas H.

Anaphylaxis within the chemotherapy setting explained
pp. 12-13(2)
Author: Nendick M.E.

Every nurse a leader!
pp. 13-13(1)
Author: Dellepoort W.T.A.

Interactive session. Ambulatory infusional therapy
pp. 14-14(1)
Authors: Oakley C.; Wright E.

A nurse's guide to the Internet
pp. 14-14(1)
Authors: Krcmar H.; Krcmar C.

Ambulatory infusional therapy - Workshop
pp. 14-14(1)
Author: Jocham H.

Stem cell transplantation, a treatment for patients with solid tumours and haematological malignancies. Implications for oncology nursing practice
pp. 14-14(1)
Author: Larsen J.

Research in oncology nursing: the way forward
pp. 15-15(1)
Author: Di Giulio P.

The research practice interface
pp. 15-15(1)
Author: Rafferty A.M.

Bridging over the gap: foundation of a nursing research committee in order to achieve research based care of haematology and oncology patients
pp. 16-16(1)
Authors: Schoenmakers J.F.; van Nierop G.; de Graaf J.P.; Pison E.C.

To be on a side track... a qualitative study of BMT patients with focus on the transition from long time hospitalisation and physical isolation to being back home again
pp. 16-16(1)
Author: Esbensen B.A.

Selecting hermeneutic phenomenology as a research methodology in cancer nursing: a clinical perspective
pp. 16-16(1)
Author: Foy S.

The validity of faecal occult blood (FOB) testing in population screening for colorectal cancer (CRC)
pp. 16-16(1)
Authors: Craven O.; Meah S.

Central venous access ports-pros and cons: a nursing perspective
pp. 17-17(1)
Authors: Myburgh L.; van Vuuren M.J.; Raats J.I.

Pain of cancer patients in radiation therapy
pp. 17-17(1)
Authors: De la Fuente y Briones F.; Buchborn K.; Bormeth S.; Zander-Heinz A.C.; Budischewski K.; Bottcher H.D.

Cancer care: priorities for nurses - Evaluation of a workshop on infections
pp. 17-17(1)
Authors: Thain C.W.; Ion E.; Podmore L.; Woods S.

A comparative study of fatigue in patients who have completed a course of chemotherapy and health individuals
pp. 17-17(1)
Authors: Nicholas E.C.; Richardson A.

Assessment of alternative and complimentary medicines and devices in cancer patients attending a multi-disciplinary cancer centre
pp. 17-18(2)
Authors: Harris L.; Naidoo S.; Vorobiof D.A.; Chasen M.R.

Continous infusion therapy: for how long can a Huber needle be left in situ without being changed? Use of a non adherent silicone dressing (Mepitel) under the Huber needle in order to prevent sores in obese patients and in patients with a deep port-a-cath
pp. 18-18(1)
Authors: Milani A.; Lunghi L.; Vernizzi S.; Passoni C.; Sociale O.; Macciola F.; Ravenna S.; Remoli S.; Grimaldi C.; Sciancalepore N.

The research nurses role in the study of patients recieving once weekly radiotherapy for locally advanced or recurrent rectal cancer
pp. 18-18(1)
Authors: Brooker S.; Tait D.; Glees J.P.; Cook A.; Norman A.

Does exist an oncological patient profile who use alternative therapies?
pp. 18-18(1)
Authors: Fernandez P.; Martinez I.; Iglesias I.; Eito C.; Fernandez I.

Empowering the cancer patient with chronic pain
pp. 18-18(1)
Authors: de Ruijter W.; van Dam F.S.A.M.; Jongkind J.F.; Witkamp F.E.; de Wit R.; Passchier J.; Vecht C.J.

Relating information needs to the cancer experience: the perspectives of people with cancer
pp. 18-19(2)
Author: van der Molen B.

Two out of three cancer patients receiving chemotherapy experience fatique
pp. 19-19(1)
Authors: Tanghe A.; Evers G.; Spinnoy M.

Fatigue in breastcancer patients undergoing adjuvant chemotherapy
pp. 19-19(1)
Authors: de Jong N.; Courtens A.M.; Schouten H.

Reflections on the challenges of conducting international, multi-institutional research - Assessment of cancer-related fatique
pp. 19-19(1)
Authors: Richardson A.; Ream E.K.; Piper B.F.; Dodd M.J.

Breast cancer screening in older women: a dual site intervention study Northeast/Southeast USA
pp. 19-19(1)
Authors: Wood R.; Morris S.; Watson M.

Measuring attitudes of oncology health professionals towards elderly people with cancer
pp. 20-20(1)
Authors: Miller M.; Kearney N.; Smith K.

Information needs of newly diagnosed cancer patients
pp. 20-20(1)
Author: Ablett-Spence I.

The development of an instrument to assess patients' experiences of side effects of cytotoxic chemotherapy
pp. 20-20(1)
Authors: Brown V.; Sitzia J.; Richardson A.; Hughes J.; Yeomans J.; Hannon H.; Dikken C.

Prevalence and distress of taste loss after radiotherapy of head and neck
pp. 20-20(1)
Authors: Evers G.; Huygh I.; Van Den Bogaert W.; Vandevelde G.

Validation of a French version of the Piper Fatigue Scale (PFS)
pp. 20-20(1)
Authors: Gledhill J.A.; Boisvert C.; Mahe C.; Rodary C.

Design of a longitudinal perspective study of fatigue in patients with cancer
pp. 21-21(1)
Authors: Robertshaw H.; Richardson A.

Chronic breast/chest wall pain following treatment for breast cancer - A research nurse led study
pp. 21-21(1)
Author: Moat S.L.

Provision of information concerning gynaecological cancer and sexuality: the patient's perspective
pp. 21-21(1)
Authors: Gamel C.; Hengeveld M.; Grypdonck M.; Davis B.

Assessing chemotherapy side effects - A critical review of symptom assessment tools
pp. 21-21(1)
Author: Brown V.

A practical screening form for the nutritional status of hospitalized patients
pp. 21-21(1)
Authors: de Kruif J.T.C.M.; Vos A.; van Vroonhoven T.J.M.V.

What are the 'needs' of cancer patients and their main carers?
pp. 21-22(2)
Authors: Thomas C.; Morris S.; McIllmurray M.B.; Soothill K.; Ledwith F.; Francis B.

Antiemetic therapy in colon cancer patients
pp. 22-22(1)
Authors: Rossi P.; Accardi C.; Augugliaro A.; Bertini F.; Brini G.; Cappelli C.; Nicoletti E.

Prevention of vaginal agglutination by women treated with radiotherapy for cervical cancer
pp. 22-22(1)
Authors: Hansen A.H.; Fruerlund L.

IntraDose&unknown; (cisplatin/epinephrine) injectable gel for treatment of neoplasms involving the liver: implications for nursing practice
pp. 22-22(1)
Author: Hupkes M.

The comparative efficacy of counselling & complementary therapy on the minimisation of psychological morbidity in a population of cancer patients
pp. 22-22(1)
Author: Seddon L.

Hospice at home: baseline study: an evaluation of palliative admissions in north Glasgow
pp. 22-23(2)
Authors: Graham J.; McGill M.; Deeny M.; Doubal A.; Meldrum T.; Welsh J.

Patient's diary (PD) is the guarantee of quality and safety of clinical trial with CAMPTO
pp. 23-23(1)
Authors: Zarouk V.; Besova N.

Development and evaluation of information materials for non-English speaking patients
pp. 23-23(1)
Authors: Speechley V.; Mallett J.

Staff knowledge and attitudes towards cancer pain management on general surgical wards: identifying educational needs
pp. 23-23(1)
Authors: Wells M.; Dryden H.; Guild P.; Farrer K.; Levack P.; Mackie G.

Accreditation of educational programmes
pp. 24-24(1)
Author: Vaessen G.

EONS core curriculum
pp. 24-24(1)
Author: Redmond K.

This house believes that nursing research is irrelevant
pp. 25-25(1)
Author: Ambaum E.W.C.

Globalizing quality in clinical trials: a nursing perspective on the main changes in the International conference on Harmonization Good Clinical Practice (ICH-GCP) guideline
pp. 26-26(1)
Author: de Boer M.

The implications of GCP for the organisation of a Clinical Trial (CT)
pp. 26-26(1)
Author: Colussi A.M.

The ICH-GCP guideline: the patient perspective - Symposium EORTC- Oncology Nursing Study Group
pp. 26-26(1)
Author: Ambaum E.W.C.

The ICH-GCP guidelines: the nursing perspective
pp. 26-26(1)
Author: Molin C.M.

Developing evidence based guidelines
pp. 27-27(1)
Author: Magnusson K.

Reviewing the evidence
pp. 27-27(1)
Author: Uitterhoeve R.

Reviewing the evidence
pp. 27-27(1)
Author: Panfil E.-M.

Writing for publication
pp. 27-27(1)
Author: Robinson L.

Cancer and its consequences on sexuality
pp. 29-29(1)
Author: Borg T.

Nursing care interventions based on theory and scientific evidence - Implications for justifying radiation oncology nursing practice
pp. 29-29(1)
Authors: Wengstrom Y.; Forsberg C.

Beating fatigue: evaluation of a programme developed to assist patients receiving chemotherapy cope with fatigue
pp. 30-30(1)
Authors: Ream E.; Richardson A.

Treatment of platinum-induced anaemia with epoetin alpha (EPO): attitudes of community and hospital based nursing staff
pp. 30-30(1)
Authors: Deary A.; Dalton L.; Kaminski E.; Thomas R.

Lymphoedema: a retrospective analysis of 196 patients at a large cancer centre, to identify if seroma following axillary dissection for breast cancer is a risk factor for lymphoedema
pp. 30-30(1)
Author: Compton L.

Treatment of breast cancer related lymphedema with or without manual lymphatic drainage: a randomized study
pp. 30-31(2)
Authors: Andersen L.; Hojris I.; Andersen J.

Promoting health: challenges within the population with breast cancer related lymphoedema
pp. 31-31(1)
Author: MacLaren J.

Transdermal fentanyl use in Greek patients with cancer-related pain
pp. 31-31(1)
Authors: Viha A.; Iconomou G.; Kalofonos H.P.; Vagenakis A.

The concept of hope and its relevance to the cancer setting
pp. 31-31(1)
Author: Porter H.

Treatment for cervical cancer can have serious implications: a way forward. Sexual dysfunction following radiation both internal and external beams has been a silent unspoken problem for years
pp. 31-31(1)
Author: Thomas J.

Nonmorphinic analgesic combinations in pain treatment for cancer
pp. 31-31(1)
Authors: Omet L.; Grigorescu A.C.

A comparison of the neurological toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC)
pp. 32-32(1)
Authors: Bacon M.; Zee B.; James K.; Stuart G.; Soroka D.; Walsh W.; Bacon E.

Cold-cap - Keeps the head cold and help some women avoiding alopecia through chemotherapy treatment for ovarian cancer
pp. 32-32(1)
Authors: Tronstad A.K.; Hanshus A.C.; Skogsfjord K.; Storing E.

Scalp cooling for chemotherapy induced alopecia: devising and implementing a unified trust policy
pp. 32-32(1)
Authors: Brewer D.; Mans L.

Prevention of lymphoedema: a booklet for Greek women with breast cancer
pp. 32-32(1)
Authors: Pappa D.; Patiraki E.; Chrysanthou V.

Skin and nail disorders: one of the specific non-hematological side effects of docetaxel (taxotere)
pp. 32-32(1)
Author: De Gucht L.

Clinical experience of ketamine for intractable neuropathic cancer pain
pp. 32-33(2)
Authors: Mula C.; Penfold R.; Makin W.P.; Smith E.

Multi-professional core care planning: a model to ensure evidence based practice
pp. 33-33(1)
Author: Porter H.

The information needs of women contemplating breast reconstruction after a diagnosis of breast cancer: a pilot study
pp. 33-33(1)
Author: Dryden H.

After mastectomy: the nurse's counselling role in breast reconstruction
pp. 33-33(1)
Author: Ferrario R.

How safe are the patients in your care? The nurses's responsibility for equipment safety-selection, purchasing, maintenance, training and the millennium issues
pp. 33-33(1)
Author: Dolan S.

Chemotherapy administration by nurses: an audit of practice and educational preparation
pp. 34-34(1)
Author: Grundy M.

Important remarks by the preparation and administering of cytotoxic drugs
pp. 34-34(1)
Authors: Claes V.; De Gucht L.; Dhaenekint C.; Ponnet G.; Roeffaers J.; Simons L.; Van Ackerbroeck G.; Van Gaver J.; Van Soom J.; Verpoorten L.; Vranckx P.

The audit results of in-patient chemotherapy management in an acute medical ward
pp. 34-34(1)
Author: Bagnall S.

Qualifying clinical trail nurses - A danish case stoty
pp. 34-34(1)
Authors: Brinch A.; Lyngsoe M.; Hostrup P.

A prospective survey of patient satisfaction with the information provided prior to admission to the H.D.U. following major surgery for cancer
pp. 34-34(1)
Author: Dolan S.

The Blood Transfusion Committee necessary evil - or a major contribution to the patient's care
pp. 35-35(1)
Author: Dolan S.

Promoting clinical effectiveness in intravenous therapy
pp. 35-35(1)
Authors: Todd J.; Bravery K.

Autologous peripheral blood stem cell transplantation (PBSCT): ''patient booklet''
pp. 35-35(1)
Authors: Van den Bosch S.; Bernasconi D.; De Bartolomei R.; Del Fedele P.; Delle Donne C.; Seminatore M.; Ghielmini M.; Cavalli F.

The use of administrative tools in clinical trials to improve the quality and systemisation of data: the responsibility of the Research Nurse
pp. 35-35(1)
Authors: Nicolaisen K.; Christiansen B.

An audit of 100 deaths at a regional cancer centre
pp. 35-35(1)
Authors: Penfold R.; Mula C.; Makin W.

Nursing responsibilities in clinical trials in the Istanbul University Oncology Institute and the implementation of education programmes
pp. 36-36(1)
Authors: Topuz E.; Aydiner A.; Durna Z.

Qualifying the palliative care at the Roskilde County Hospital - A quality development project
pp. 36-36(1)
Authors: Esbensen B.A.; Andersen S.; Begelund J.; Johnsen L.; Ottesen S.S.

Venous central line management and complications in patients treated with high-dose chemotherapy and circulating hemopoietic progenitor support (PBPC)
pp. 36-36(1)
Authors: Gini S.; Guarguaglini E.; Gambini L.; Buonamini I.; Fonti G.; Benanti F.; Bengala C.; Galli L.; Antonuzzo A.; Conte P.F.

The communication of bad news - A Rotterdam perspective
pp. 36-36(1)
Authors: Koorevaar C.A.; Neeleman W.B.; Rehorst J.; Stojanoski A.

Safe handling of cytotoxic drugs in Slovenia
pp. 36-37(2)
Authors: Bobnar A.; Velepic M.

Intensity Modulated Radiotherapy (IMRT) of prostate cancer: a greater demand for quality control and daily treatment accuracy
pp. 37-37(1)
Authors: Bate M.-T.; Demeerleer G.; Van Duyse B.; Vakaet L.; De Neve W.

The need for frequent stimulation and help of the investigators for a good managment in the ''TDM study''
pp. 37-37(1)
Authors: Heilmann M.-O.; Trillet-Lenoir V.

Comfortable patients in protocoled trials
pp. 37-37(1)
Authors: Pedersen I.R.; Akselbo L.

Guideline for patients undergoing chemoembolization
pp. 37-37(1)
Authors: Salazar J.; Villena M.P.; Vilugron E.; Orlandi F.J.

Use of alginate dressings in the care of chronic wound
pp. 37-37(1)
Authors: Ursic H.; Salehar A.

Europe against cancer programme - Overview of advancing cancer nursing practice project
pp. 38-38(1)
Author: Knowles G.

Advancing cancer nursing practice: educating advanced practitioners
pp. 38-38(1)
Authors: Di Giulio P.; Saiani L.; Brugnolli A.

Using research findings: is it really possible
pp. 38-38(1)
Authors: Uitterhoeve R.; Ambaum B.

Anxiety levels in family caregivers of cancer patients receiving chemotherapy
pp. 38-38(1)
Authors: Patiraki E.; Gika M.; Pappa D.; Kiritsi H.; Haralambidou E.; Anagnostopoulos F.

Advancing cancer nursing practice
pp. 39-39(1)
Author: Corner J.

What constitutes good cancer care in Greece
pp. 39-39(1)
Author: Efstathiou N.

Therapeutic communications
pp. 40-40(1)
Author: Lanceley A.

Advances in pain management require new nursing skills
pp. 40-40(1)
Authors: Vogelaar P.J.W.; Crul B.J.P.

Extravasation bei intravenoser Chemotherapie anhand von Pflegestandards
pp. 40-40(1)
Author: Wimmer E.

New perspectives on fatigue
pp. 40-40(1)
Author: Ream E.

Recent developments in palliative care
pp. 41-41(1)
Author: Kealy K.

Cancer nursing in the new millennium: non-persons or the people in the big house
pp. 41-41(1)
Author: Kearney N.

Managing patients at home during the aplastic phase of high dose chemotherapy with autologous peripheral blood stem cell transplantation (APBSCT)
pp. 42-42(1)
Authors: Holtkamp M.J.; Westermann A.M.; Linthorst G.A.M.; Uyterlinde W.I.; van Leeuwen L.; Willemse E.J.M.; Rodenhuis S.

Evaluation of advanced home care (AHC). The next-of-kin's experiences
pp. 42-42(1)
Authors: Rollison B.; Carlsson M.

An exploratory study investigating the experiences of patients and nurses with a nurse led peripherally inserted central venous catheter line service
pp. 42-42(1)
Authors: Oakley C.; Wright E.; Ream E.

The role of the radiotherapy research nurse
pp. 42-43(2)
Author: Brooker S.

Outpatient parenteral antibiotic therapy (OPAT) in patients with acute leukaemia (AL) and aggressive non-Hodgkin's lymphoma (NHL)
pp. 43-43(1)
Authors: Johansson E.; Bjorkholm M.; Wredling R.; Engervall P.

Cancer diagnosis: the nurses role in breaking the bad news
pp. 43-43(1)
Author: Kogelbauer C.

A specialist nurse service for patients with lung cancer: a review of the first year
pp. 43-43(1)
Author: Johnson M.

A study of contraceptive advice given to chemotherapy patients
pp. 43-44(2)
Author: Lomax L.

Oncologic nursing evaluation at the Galician comunity
pp. 44-44(1)
Authors: Davila E.; Diaz F.

Zoledronate, a new 3^rd generation bisphosphonate: implications for nursing practice
pp. 44-44(1)
Authors: Hupkes M.; Givant F.

Family rooms at hospitals - Combining the advantages of the hospice and the facilities of the public hospital
pp. 44-44(1)
Authors: Linderoth H.R.; Jorgensen C.H.

Management of the outpatient clinic in a breast cancer unit
pp. 44-44(1)
Authors: Rubio G.; Rossetti B.; Bernasconi P.

A multi-disciplinary 'outcome' round to decrease stress and burnout among Bone Marrow Transplant nurses and to promote disscussion and education; one year on
pp. 44-44(1)
Author: Stephens M.

Increased willingness for organ donation in cancer patients
pp. 44-45(2)
Authors: Muller A.; Kretschmar C.; Horn I.; Landenberger M.

The role of the research sister in MRI/oncology
pp. 45-45(1)
Author: Price N.

A new approach for nurses new to oncology nursing
pp. 45-45(1)
Authors: Burton A.; Witham G.

Harvesting of peripheral blood stem cells using venesection and subsequent reinfusion of whole blood
pp. 45-45(1)
Authors: Hodgetts J.; Lomax L.

Handbook for administration of cytostatic agents in order to obtain uniformity in dealing with these
pp. 45-45(1)
Author: Nielsen E.

Application of educational programme ''To Learn How to Live with Cancer'' in patients with breast cancer for psychosocial adaptation
pp. 45-45(1)
Authors: Milovic L.; Nikolic S.; Djurdjevic A.

Clinical paths: to increase the quality of nursing in a haematologic center
pp. 45-46(2)
Authors: Van Asch L.; Gelissen L.; Van Clapdurp C.; Casteels R.; Daniels J.; Zachee P.

An interactive patient information CD ROM on specific side effects in chemo- and radiotherapy
pp. 46-46(1)
Authors: Vandevelde G.; Peeters J.; Ponnet G.; Vandebotermet J.; Verpoorten L.

Why oncology units should provide a website for their patients
pp. 46-46(1)
Authors: Dalton L.; Deary A.; Akass K.; Thomas R.

Caring for cancer patients in diverse healthcare environments - Meeting the challenge to educate nurses and healthcare professionals
pp. 46-46(1)
Authors: Davidge E.M.; Freemantle A.G.

Job sharing senior clinical roles: heaven or hell!
pp. 46-47(2)
Authors: Cathmoir D.; Mullooly C.; Brewer D.; Miller C.

The development and implementation of a clinical pathway for the diagnosis and staging of lymphoma
pp. 47-47(1)
Authors: Vanhaecht K.; Sermeus W.; Paridaens R.; Thomas J.

Fatigue in cancer, a new education course for nurses
pp. 47-47(1)
Authors: Hummel H.; Rietema R.; Vaessen G.

Hospice as a resource centre pilot project. Nursing staff education in the principles of palliative care in private nursing homes
pp. 47-47(1)
Authors: Fergus L.; Munroe S.; McGill M.; Paterson I.

Recovery & stability, health promotion and rehabilitation for cancer patients
pp. 47-47(1)
Authors: Gijsen B.C.M.; de la Fonteijne J.M.J.; van den Borne H.W.; Vlaeyen J.W.S.

Surviving changes in health care
pp. 48-48(1)
Author: Krasuska M.E.

Post-Basic Courses in Cancer Nursing - The impact of continuing education
pp. 48-48(1)
Author: Bachmann-Mettler I.

Leadership in cancer nursing care
pp. 48-48(1)
Author: Ferguson A.

Speaker against: this house believes that nurses are able to meet patients' health care needs
pp. 49-49(1)
Author: Luker K.A.

Speaker in favour: this house believes that nurses are able to meet patients' health care needs
pp. 49-49(1)
Author: Tishelman C.

Management issues associated with inherited cancer risk
pp. 53-53(1)
Author: Daly P.A.

Impact of the genetic revolution on nursing practice
pp. 53-53(1)
Author: Ormiston W.J.

Genetics: a hope for prevention
pp. 54-54(1)
Author: Murphy A.E.

Does modern oncology need medical genetics?
pp. 54-54(1)
Author: Murday V.

Psychosocial issues in cancer genetics - Progress and prospects
pp. 54-54(1)
Author: Cull A.

The experience of hereditary cancer in families - implications for cancer genetics counselling
pp. 54-54(1)
Author: Ardern-Jones A.

Translating research into practice: the clinician's point of view
pp. 55-55(1)
Author: Hossfeld D.K.

Evidence based nursing. The key for professional nursing
pp. 55-55(1)
Author: Beirer A.

Good clinical practice: a label of quality?
pp. 57-57(1)
Author: Therasse P.

Is our daily nursing practice Good Clinical Practice?
pp. 57-57(1)
Author: Tanghe A.

Cost of treating colorectal cancers
pp. 58-58(1)
Author: Kerr D.J.

The impact of telematics and information technology on the management of oncology care
pp. 58-58(1)
Authors: Sermeus W.; Vanhaecht K.; Kearney N.; Hoy D.; Delesie L.; Hofdijk J.; Kinnunen J.; Mantas J.; Gypen T.; Tansley J.

The costs and benefits of nurse led cancer care
pp. 58-58(1)
Author: Corner J.

Usefulness of medico-economic studies in cancer care from the perspective of payers and policy makers?
pp. 59-59(1)
Author: Viens G.

Parenteral infusion from hospital to home treatment: cost-effective?
pp. 61-61(1)
Authors: Witteveen P.O.; Van Boxtel A.J.H.

Parenteral infusion from hospital to home treatment: a feasible option?
pp. 61-61(1)
Authors: Van Boxtel A.J.H.; Witteveen P.O.

Cancer treatment - Major questions for the new millennium
pp. 65-65(1)
Author: McVie J.G.

Paediatric tumours - What have we learnt? General messages for oncologists
pp. 65-65(1)
Author: Gadner H.

The impact of biology on the practice of radiotherapy
pp. 65-65(1)
Author: James N.

Vascular endothelial growth factors and receptors involved in angiogenesis and lymphangiogenesis
pp. 65-66(2)
Author: Alitalo K.

New imaging methods illuminating cellular structure and function
pp. 66-66(1)
Author: Pepperkok R.

Rationale of the optimal interaction chemotherapy-radiotherapy
pp. 66-66(1)
Author: Lukas P.

Continuing medical education - The European agenda
pp. 66-66(1)
Author: Geraghty J.

The impact of surgical training workshops on the outcome in rectal cancer in the population of Stockholm
pp. 67-67(1)
Authors: Lehander A.; Holm T.; Rutqvist L.E.; Moran B.J.; Heald R.J.; Cedermark B.

Preop chemoradiation (CTRT) +/- postop chemo (CT) in locally advanced rectal cancer. Preliminary results
pp. 67-67(1)
Authors: Cionini L.; Cartei F.; Valentini V.; Lupattelli M.; Pizzi G.B.; Osti M.; Friso M.L.; Santoni R.; Vidali C.; De Paoli A.

Influence of the interval between pre operative radiotherapy (preop RXT) and surgery on downstaging and sphincter preservation for rectal cancer. The LYON R90 01 randomized trial
pp. 67-67(1)
Authors: Gerard J.P.; Francois Y.; Nemoz C.; Adeleine P.

In vivo monitoring of tumor microcirculation changes during radiotherapy in patients with rectal carcinomas: preliminary results and possible implications for therapy
pp. 67-68(2)
Authors: DeVries A.; Griebel J.; Kremser C.; Hoflehner J.; Ofner D.; Debbage P.; Lukas P.

Disseminated tumor cells detected by CK 20 RT-PCR in the blood and the bone marrow of patients with colorectal carcinoma represent an independent prognostic factor
pp. 68-68(1)
Authors: Vogel I.; Soeth E.; Roder C.; Kremer B.; Kalthoff H.; Henne-Bruns D.

Phase III trial of 5-fluorouracil (5FU) and leucovorin (LV) with or without trimetrexate (TMTX) as first line treatment in advanced colorectal cancer (ACC)
pp. 68-68(1)
Authors: Punt C.J.A.; Keizer H.J.; Douma J.; Schuller J.; Skovsgaard T.; ten Napel C.H.H.; Lochs H.; Muller E.W.; Russell L.; Wagener D.J.T.

Irinotecan (Iri) in combination with high-dose infusional (HDI) 5FU/FA either weekly or bi-weekly: evidence of survival advantage and quality of life (QoL) improvement in metastatic colorectal cancer (MCRC)
pp. 68-68(1)
Authors: Rougier P.; Cunningham D.; Roth A.D.; Germa J.R.; James R.D.; Karasek P.; Jandik P.; Iveson T.; Carmichael J.; Gruia G.; Alakl M.; Sibaud D.; Douillard J.Y.

Medical resource use in a phase III trial (SO 14796) of XelodaTM (capecitabine) in previously untreated advanced/metastatic colorectal cancer
pp. 68-69(2)
Authors: Twelves C.; Van Cutsem E.; Hieke K.; Barker C.; Jamieson C.; Hornberger J.; Garrison L.; Osterwalder B.; Thibault A.

Functional results after total mesorectal excision (TME) in rectal cancer
pp. 69-69(1)
Authors: Oosterhuis J.W.A.; van Berlo C.L.H.; Reinders J.F.M.

Late side effects of combined treatment modalities in rectal cancer
pp. 69-69(1)
Authors: Jacob-Heutmann D.; Thilmann C.; Adamietz I.A.; Bottcher H.D.

Liver resection after preop. chemotherapy for colorectal metastases: morbidity and treatment results
pp. 69-69(1)
Authors: Hohenberger P.; Kilpert B.; Schlag P.M.

Artificial neural network prediction of 5-year survival from colon cancer
pp. 69-69(1)
Authors: Jessop J.M.; Snow P.; Brandt J.; Bellucco C.; Menck H.R.; Kerr D.J.

Postoperative radiation (RT) and concomitant bolus fluorouracil (FU) with or without additional chemotherapy (CT) as adjuvant treatment in patients with high risk rectal cancer. A randomized phase III study conducted by the Hellenic Cooperative Oncology Group
pp. 69-70(2)
Authors: Athanassiou E.; Dafni U.; Liaros A.; Briassoulis E.; Samantas E.; Kosmidis P.; Skarlos D.; Pavlidis N.; Fountzilas G.

A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), ''Mayo regimen'', in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)
pp. 70-70(1)
Authors: Pozzo C.; Pyrhonen S.; Bodrogi I.; Szanto J.; Kamica-Mlodkowska H.; Starkammar H.; Izso J.; Hansen P.; Kjaer M.; Noel N.; Gruia G.; Barone C.

A pilot study of a feasibility and economic analysis of home based chemotherapy in advanced colorectal cancer
pp. 70-70(1)
Authors: Ingleby S.; Bamwell J.; Baker J.; Harvey P.; Kerr D.J.; Law V.; Young A.

Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU)
pp. 70-70(1)
Authors: Cascinu S.; Aschele C.; Barni S.; Debernardis D.; Baldo C.; Tunesi G.; Catalano V.; Giordani P.; Baldelli A.M.; Catalano G.

Prospective study of adjuvant therapy with monoclonal antibody 17-1A of Dukes' B2/B3-colon carcinoma - Interim analysis of toxicity
pp. 70-70(1)
Authors: Queisser W.; Franz A.; Hartung G.; Sturm J.; Edler L.; Bornbusch D.; Dietrich G.; Bollinger C.; Gonnermann M.; Wojatschek C.

Once weekly radiotherapy for patients with locally advanced or recurrent rectal cancer
pp. 71-71(1)
Authors: Tait D.; Glees J.P.; Cook A.; Brooker S.; Norman A.

Adjuvant combined radiochemotherapy in rectal cancer
pp. 71-71(1)
Authors: Messer P.M.; Welte B.; Suhr P.; Link K.H.; Rottinger E.M.; Beger H.G.

CPT-11 and L-OHP combination versus alternated combination of LV5FU2 + CPT-11/LV5FU2 + L-OHP in 5-FU resistant advanced colorectal cancer (CRC): Preliminary results
pp. 71-71(1)
Authors: Becouarn Y.; Mousseau M.; Gamelin E.; Coudert B.; Marceau-suissa J.; Bekradda M.

Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial
pp. 71-71(1)
Authors: Maiello E.; Giuliani F.; Gebbia V.; Cigolari S.; Fortunato S.; Paoletti G.; Borsellino N.; Lopez M.; Gebbia N.; Colucci G.

Chronomodulated (chrono) infusion of 5-fluorouracil (5-FU) and 1-folinic acid (FA) in 91 patients (pts) with metastatic colorectal cancer: the Regina Elena Cancer Institute experience
pp. 71-72(2)
Authors: Garufi C.; Aschelter A.M.; Zappala A.; D' Attino R.M.; Antonini C.G.C.; Rosati N.; Nistico C.; Cosimelli M.; Giannarelli D.; Terzoli E.

Qualitative and chronological assessment of toxicities during treatment with raltitrexed ('Tomudex') in 861 patients: implications for patient management
pp. 72-72(1)
Authors: Garcia-Vargas J.E.; Sahmoud T.; Smith M.P.; Green S.

'Tomudex' (raltitrexed) plus radiotherapy as post-operative treatment or palliative treatment for patients with rectal cancer: phase I studies
pp. 72-72(1)
Authors: Price P.; James R.; Smith M.

Characterization of genetic subtypes of colorectal cancers
pp. 72-72(1)
Authors: Csuka O.; Doleschall Z.; Kamory E.; Toth K.; Peter I.; Koves I.; Rahoty P.; Vamosi-Nagy I.; Otto S.

Randomized phase II study of CPT-11 plus mitomycin C versus oxaliplatin plus mitomycin C in previously treated patients with advanced colorectal cancer (ACC)
pp. 72-73(2)
Authors: Ulrich-Pur H.; Brugger S.; Kornek G.V.; Fiebiger W.; Haider K.; Kwasny W.; Depisch D.; Kovats E.; Lang F.; Scheithauer W.

Preoperative chemoradiation plus intraoperative presacral electrons in T3-4 Nx M0 primary rectal cancer: early single institution experience
pp. 73-73(1)
Authors: Calvo F.A.; Cantalapiedra R.; Marcos P.; Del Valle E.; Munoz F.; Garcia-Sabrido J.L.; Gomez M.; Lozano M.A.

A prospective comparison of in-patient versus outpatient DeGramont therapy: using quality of life, acceptability and response measures: a pilot study
pp. 73-73(1)
Authors: Rowe M.; James R.

Disease oriented treatment of metastatic colorectal cancer (CRC) with dose-dense 5-FU/Folinic acid (FU/FA) combination chemotherapy
pp. 73-73(1)
Authors: Loeffler T.M.; Droege C.; Lenfers B.H.M.; Hausamen T.U.

Prevention and treatment of carcinomatosis from colorectal malignancy
pp. 73-74(2)
Author: Sugarbaker P.H.

The prognostic significance of elevated serum CA19-9 level in patients with metastatic colorectal cancer
pp. 74-74(1)
Authors: Wong A.; Chan A.K.P.

Screening for HNPCC-focussing on families
pp. 74-74(1)
Authors: Sahm S.; Raedle J.; Schmied A.; Caspary W.; Zeuzem S.

'Tomudex' (raltitrexed) plus 5FU combination treatment for patients with advanced colorectal cancer: a Phase I study
pp. 74-74(1)
Authors: Mayer S.; Hilger R.; Muller C.; Dohmen D.; Kloeppel R.; Vanhoefer U.; Scheulen M.E.; Seeber S.; Harstick A.

'Tomudex' (raltitrexed) plus 5-fluorouracil: a promising option for the treatment of patients with metastatic colorectal cancer
pp. 74-74(1)
Authors: Schwartz G.K.; Bertino J.; Kemeny N.; Saltz L.; Kelsen D.K.; Tong W.; Barazzuol J.; Lowery C.; Smith M.

'Tomudex' (raltitrexed) 4.0 mg/m[2] as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II study
pp. 75-75(1)
Authors: Schulz A.; Garfield D.; Berry W.; Gordon D.; Lowery C.; Smith M.

Second line treatment with irinotecan (CPT11) in patients (pts) with advanced colo-rectal carcinoma (ACRC) resistant to 5FU
pp. 75-75(1)
Authors: Barcelo J.R.; Rubio I.; Fernandez R.; Mane J.M.; Munoz A.; Abon G.; Fuente N.; Lopez-Vivanco G.

A phase II trial of pre-operative radiation therapy with concomitant 5-FU and sphincter-sparing surgery (preliminary results)
pp. 75-75(1)
Authors: Ozkan L.; Zorluoglu A.; Yilmazlar T.; Kahraman S.; Engin K.

'Tomudex' (raltitrexed) plus oxaliplatin (Eloxatin) in previously untreated metastatic colorectal cancer (MCRC) patients: an active combination
pp. 75-75(1)
Authors: Bennouna J.; Seitz J.F.; Paillot B.; Gamelin E.; Francois E.; Conroy T.; Raoul J.L.; Becouarn Y.; Cvitkovic F.B.; Nasca S.; Ychou M.; Jacob J.; Smith M.; Douillard J.Y.; Fandi A.

Preoperative chemoradiation for T3-T4 rectal cancer acute toxicity and tumor response our experience
pp. 76-76(1)
Authors: Friso M.L.; Loreggian L.; Lora O.; Baiocchi C.; Fasano C.; Pucciarelli S.; Fornasiero A.; Sotti G.

Phase I/II study of oxaliplatin (L-OHP) plus 5-Fluorouracil concurrent with external beam radiotherapy (EBRT) in rectosigmoidcarcinoma
pp. 76-76(1)
Authors: Ramon y Cajal T.; Rayo S.G.; Calvo E.; Aristu J.J.; Villafranca E.; Canon R.; Moreno M.; Hernandez J.L.; Azinovic I.

Expression of the erbB family in colorectal adenocarcinoma
pp. 76-76(1)
Authors: Kapitanovic S.; Radosevic S.; Ferencic Z.; Spaventi S.; Pavelic K.; Spaventi R.

Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation
pp. 76-76(1)
Authors: Avital S.; Haddad R.; Troitsa A.; Kashtan H.; Brazovsky E.; Gitstein G.; Skornick Y.; Schneebaum S.

Mutations in repeated sequences within cancer genes in sporadic replication error positive colorectal cancers
pp. 76-76(1)
Authors: Fiorente P.; Cariola F.; Nanna P.; Gristina R.; Leo S.; Gentile M.

Severe toxicity of a standard 5-FU/Leucovorin combination in patients with colorectal cancer: a prospective study
pp. 77-77(1)
Authors: Tsalic M.; Bar-Sela G.; Menashe N.; Vizel B.; Haim N.

Tyrosine phosphatases in integrin-mediated cell adhesion to collagen under static and dynamic flow conditions
pp. 77-77(1)
Authors: Haier J.; Nasralla M.; Nicolson G.L.

Randomized trial of 5-Fluorouracil (5-FU)-Levamisol (LEV) versus 5FU-LEV-Leucovorin (LV) in patients with colorrectal cancer stage II and III. Eigth years results
pp. 77-77(1)
Authors: Murias A.; Aguiar J.; Bohn U.; Molano F.; Almenarez J.; Garcia I.; Diaz-Chico J.C.

Relationship between s-phase fraction and clinical outcome after surgery for colorectal carcinoma
pp. 77-77(1)
Authors: Cianchi F.; Balzi M.; Becciolini A.; Faraoni P.; Pucciani F.; Perigli G.; Bechi P.; Palomba A.; Ciancio G.; Cortesini C.

Oral uracil/tegafur (UFT) plus leucovorin (LV) in patients with metastatic colorectal cancer (CRC)
pp. 78-78(1)
Authors: Goker E.; Aykan N.F.; Serdengecti S.; Gunel N.; Alakavuklar M.; Icli F.; Yucel I.; Uskent N.; Arpaci F.; Firat D.

Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas
pp. 78-78(1)
Authors: Seong J.; Chung E.; Kim H.; Kim G.; Kim N.; Sohn S.; Min J.; Suh C.

Adjuvant 5-FU based therapy for colorectal cancer
pp. 78-78(1)
Authors: Munoz A.; Rubio I.; Mane J.M.; Barcelo J.R.; Fernandez R.; Abon G.; Fuente N.; Lopez-Vivanco G.

Fas-APO1 (CD95+) expression on peripheral blood T lymphocytes (Ly) before and after surgery in colorectal cancer (CRC) patients
pp. 78-78(1)
Authors: Donina S.; Engele L.; Jaunalksne I.; Zakenfelds G.; Citovica M.; Klestrupe I.

A bi-modality treatment of hepatic arterial therapy (HAT) of unresectable isolated colorectal liver metastases (CLM). Our experience
pp. 78-79(2)
Authors: Jafelice G.; Pittureri C.; Mazziotti A.; Jovine E.; Grazi G.L.; Golfieri R.; Giampalma M.; Piccinini E.; Di Stefano A.; Piana E.; Martoni A.; Pannuti F.

Phase I of CPT-11 (CAMPTO(R)) combined with 5-FU/folinic acid (FA) nordic schedule in first line metastatic colorectal cancer (CRC)
pp. 79-79(1)
Authors: Ristamaki R.; Glimelius B.; Linne T.; Boussard B.; Oulid-Aissa D.; Pyrhonen S.

CAMPTO(R) (CPT-11) combined with different schedules of bolus 5-FU in 1st line treatment of metastatic colorectal cancer
pp. 79-79(1)
Authors: Graeven U.; Ridwelski K.; Manns M.P.; Espana P.; Carlsson G.; Borner M.; Boussard B.; Oulid-Aissa D.; Hemmers H.; Schmiegel W.H.

Advanced colorectal cancer (ACC): impact of chronotherapy (chrono) on patients' (pts) quality of life (QoL)
pp. 79-79(1)
Authors: Pugliese P.; Garufi C.; Perrone M.; Aschelter A.M.; Zappala A.; Giannarelli D.; Cosimelli M.; Terzoli E.

The peculiarity HLA-allels and HLA-lymphocyte phenotypes in the patients of Uzbek population suffering from colorectal cancer
pp. 80-80(1)
Authors: Tukhfatullina-Gainullina Z.; Muhammadobidov S.; Rakhimova D.; Gildieva M.

Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu
pp. 80-80(1)
Authors: Beretta G.D.; Cascinu S.; Zaniboni A.; Ratti R.; Giordani P.; Catalano V.; Martignoni G.; Barni S.; Frontini L.; Labianca R.

Oxaliplatin, 5-FU and folinic acid (OFFA) as II-line chemotherapy in advanced colorectal cancer
pp. 80-80(1)
Authors: Tassinari D.; Panzini I.; Pasquini E.; Desiderio F.; Drudi G.; Fattori P.P.; Gianni L.; Oliveno G.; Tononi A.; Ravaioli A.

'Tomudex' (raltitrexed) has a manageable toxicity profile in elderly patients with metastatic colorectal cancer
pp. 80-80(1)
Authors: Facchini T.; Genet D.; Berdah J.F.; Nouyrigat P.; Dutin J.P.; Laplaige P.; Smith M.; Haguenauer D.

Preoperative radiotherapy for advanced lower rectal cancer-combination of external and high-dose-rate intraluminal radiotherapy
pp. 80-81(2)
Authors: Horikawa N.; Yoshimura H.; Tamamoto T.; Uto F.; Tsuji Y.; Ohishi H.; Asakawa I.; Uchida H.; Fujii H.; Nakano H.

A phase II study of alternating cycles of CPT-11 and high-dose 48 hour infusion 5-FU in combination with leucovorin (HD-5-FU/LV) in no selective patients with metastatic colorectal cancer (MCRC)
pp. 81-81(1)
Authors: Rosati G.; Bilancia D.; De Santis S.; Dinota A.; Rossi A.; Manzione L.

Phase-II-study of a 24-h infusion with 5-fluorouracil (5-FU) and simultaneous sodium-folinic acid in the first-line-treatment of advanced colorectal cancer: interim analysis
pp. 81-81(1)
Authors: Hofheinz R.; Hartung G.; Wein A.; Riedel C.; Kuhfahl J.; Rost A.; Brecht A.; Bolte R.; Fritze D.; Keilholz U.; Kreuser E.D.; Queisser W.

The distribution of polymorphic enzymes in colon cancer case
pp. 81-81(1)
Authors: Romer H.C.; Thier R.; Reckwitz T.; Geller F.; Buschendorf I.; Lohlein D.; Golka K.

Oxaliplatin (OX) after irinotecan (IRI): antitumour activity and clinical benefit of 3^rd and higher line chemotherapy with ox for patients (pts) with metastatic colorectal cancer (MCC) after failure of IRI
pp. 81-81(1)
Authors: Kretzschmar A.; Metzger J.; Thuss-Patience P.C.; Kaufmann C.C.; Wilhelm M.; Kroning H.; Schumacher H.; Reichardt P.

Adjuvant trial in melanoma patients comparing rIFN- to rIFN- to Iscador to a control group after curative resection of high risk primary (=<3 MM) or regional lymphnode metastasis (EORTC 18871)
pp. 82-82(1)
Authors: Kleeberg U.R.; Brocker E.B.; Lejeune F.; Chartier C.; Egger C.; Marsden J.; Ruiter D.; Suciu S.

QUASAR: a UKCCCR study of adjuvant chemotherapy (CT) for colorectal cancer
pp. 82-82(1)
Authors: Gray R.G.; Kerr D.J.; McConkey C.; Williams N.S.

Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy - A phase III EORTC study
pp. 82-82(1)
Authors: Bolla M.; Collette L.; Gonzalez D.; Warde P.; Dubois J.B.; Mirimanoff R.; Storme G.; Bernier J.; Kuten A.; Pierart M.

Randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: the EUROSCAN study
pp. 82-82(1)
Authors: van Zandwijk N.; Pastorino U.; de Vries N.; Dalesio O.; van Tinteren H.

Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5
pp. 83-83(1)
Authors: Jakesz R.; Hausmaninger H.; Samonigg H.; Kubista E.; Depisch D.; Fridrik M.; Stierer M.; Gnant M.; Steger G.; Kolb R.; Jatzko G.; Hofbauer F.; Reiner G.; Steindorfer P.

Adjuvant treatment of premenopausal breast cancer with zoladex and tamoxifen: results from randomised trials by the Cancer Research Campaign (CRC) Breast Cancer Trials Group, The Stockholm Breast Cancer Study Group, the South East Sweden Breast Cancer Group and Gruppo Interdisciplinare Valutazione Intervention Oncologia (GIVIO)
pp. 83-83(1)
Author: Nordenskjold B.

Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate
pp. 83-83(1)
Authors: Diel I.J.; Lichinitser M.R.; Body J.J.; Schlosser K.; Moecks J.; Cavalli F.; Dornoff W.; Gorbunova V.A.; McCloskey E.; Weisz J.; Kanis J.A.

Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin
pp. 83-83(1)
Authors: Mouridsen H.T.; Andersen J.; Andersson M.; Dombernowsky P.; Ejlertsen B.; Rose C.; Sorensen P.G.; Sandberg E.; Andersen K.W.; Jensen M.-B.; Bengtson N.O.; Bergh J.; Nordenskjold B.

Survival advantage of exemestane (EXE, Aromasin(R)) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study
pp. 84-84(1)
Authors: Bajetta E.; Dirix L.Y.; Fein L.E.; Jones S.E.; Cervek J.; Kaufmann M.; Fowst C.; Polli A.; di Salle E.; Massimini G.

Estrogen receptor-beta: a new form of estrogen receptor in breast cancer
pp. 84-84(1)
Authors: Cullen R.; Maguire T.M.; McDermott E.; O'Higgins N.; Duffy M.J.

HER2/neu as a predictive factor in breast cancer
pp. 84-84(1)
Authors: Piccart M.; Hamilton A.

Cytokeratin (CK)-positive bone marrow micrometastases (BMM) and survival in stage I-III breast cancer
pp. 84-84(1)
Authors: Braun S.; Pantel K.; Janni W.; Hepp F.; Kentenich C.R.M.; Muller P.; Gastroph S.

Micrometastases in sentinel node in breast cancer
pp. 85-85(1)
Authors: Barbera D.; Ellis I.O.; Geraghty J.G.

Mammographic size of ductal carcinoma in situ (DCIS) does not predict the presence of an invasive focus
pp. 85-85(1)
Authors: Wahedna Y.; Evans A.J.; Proder S.E.; Blamey R.W.; Ellis I.O.; Geraghty J.G.

Local recurrence (LR) after breast-conserving therapy (BCT) in node-negative premenopausal patients. Risk factors and influence of Peri-operative Chemotherapy (PeCT); an EORTC Breast Cancer Cooperative Group Study
pp. 85-85(1)
Authors: Elkhuizen P.H.M.; van Slooten H.J.; Clahsen P.C.; Hermans J.; van de Velde C.J.H.; van den Broek L.C.J.M.; van de Vijver M.J.

Individualised survival prediction in breast cancer (BC) based on nation-wide follow-up data: the finprog study
pp. 85-85(1)
Authors: Joensuu H.; Lundin J.; Lundin M.; Holli K.; Pylkkanen L.; Turpeennemi-Hujanen T.

Is ERBB-2 A predictive marker for response to primary chemotherapy for operable breast cancer: a prospective study in a phase ii randomized trial of doxorubicin/cyclophosphamide (AC) and doxorubicin/paclitaxel (AT)
pp. 86-86(1)
Authors: De Cremoux P.; Dieras V.; Le Doussal V.; Vincent-Salomon A.; Tubiana-Hulin M.; Pierga J.-Y.; Spyratos F.; Magdelenat H.; Pouillart P.

Her 2 positivity and ER negativity predicts the complete pathological response of breast cancers treated with primary docetaxel
pp. 86-86(1)
Authors: Payne S.; Miller I.D.; Smith I.C.; Heys S.D.; Walker L.G.; Anderson J.; Hutcheon A.W.; Ah-See A.K.; Eggleton S.P.H.; Eremin O.

Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast
pp. 86-86(1)
Authors: Loibl S.; von Minckwitz G.; Weber S.; Schini-Kerth V.; Sinn H.P.; Hildenbrand R.; Mulsch A.; Fichtlscherer B.; Kaufmann M.

Immuncytochemical detection of cytokeratin (CK)-positive micro-metastases in lymph nodes (LN) and bone marrow (BM) from node-negativ breast cancer patients with stage I-II disease
pp. 86-87(2)
Authors: Cevatli B.S.; Assemi C.; Trimpl A.; Braun S.

A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood
pp. 87-87(1)
Authors: Aerts J.; Wynendaele W.; Paridaens R.; Christiaens M.R.; Van den Bogaert W.; van Oosterom A.T.; Vandekerckhove F.

HER2 interaction with intermediate filament proteins and the influence on prognosis in breast cancer
pp. 87-87(1)
Authors: Fuchs I.; Danneschewski S.; Buhler H.; Schaller G.

C-ERB-B2 expression as a predictor of outcome in a randomized trial comparing adjuvant CMF vs single-agent epirubicin in stage I-II breast cancer (BC) patients
pp. 87-87(1)
Authors: Colozza M.; Gori S.; Mosconi A.M.; Bucciarelli E.; Bisagni G.; Rodino C.; Bian A.R.; Sabbatini R.; Mazzocchi

Predictors of axillary lymph node involvement in breast cancer <20 mm
pp. 87-88(2)
Authors: Krause A.; Gerber B.; Muller H.; Reimer T.; Richter D.; Markowitzky J.; Friese K.

Clinico-pathological characteristics of breast cancer associated with thyroid disease
pp. 88-88(1)
Authors: Montemurro F.; Cristofanilli M.; Smith T.; Asmar L.; Hortobagyi G.N.

Bcl-2 expression, cell differentiation and survival in primary breast cancer
pp. 88-88(1)
Authors: Vandebroek A.; Makar A.; Joosens E.; Van Leuven H.; Declercq S.; Beelaers W.; Van den Weyngaert D.; Gerris J.; Becquart D.; Kockx M.

Fine needle aspiration is associated with hematogenous dissemination of breast cancer cells as determined by RT-PCR
pp. 88-88(1)
Authors: Hu X.C.; Chow L.W.C.

Local Recurrence (LR) after Breast Conserving Therapy (BCT); risk factors predicting for subsequent distant metastasis
pp. 88-89(2)
Authors: Elkhuizen P.H.M.; Hermans J.; Leer J.W.H.; van den Broek L.C.J.M.; van de Vijver M.J.

Quantitation of c-erbB-2 in primary breast cancer allows identification of a further poor prognostic group
pp. 89-89(1)
Authors: Chong D.; Cooke T.G.; Reeves J.R.; George W.D.; Mallon E.A.; Ozanne B.; Stanton P.

Prognostic impact of extended extracapsular component (EEC) in involved lymph nodes (LN) in primary breast cancer (BC)
pp. 89-89(1)
Authors: Kahlert S.; Boettcher B.; Lebeau A.; Bauerfeind I.; Nestle-Kraemling C.; Untch M.

The study of breast cancer metastases to the specific group of the axillary lymph nodes
pp. 89-89(1)
Authors: Stanislawek A.; Kurylcio L.

Overexpression of p27 in relation to p53 and clinicopathologic variables in node-positive breast cancer
pp. 89-89(1)
Authors: Tsuchiya A.; Zhang G.-J.; Endo Y.; Nakamura I.; Watanabe T.; Kimijima I.; Takenoshita S.

Fatty acid synthase expression in breast carcinoma patients. Correlation with hormone receptors
pp. 90-90(1)
Authors: Nakamura I.; Kimijima I.; Zhang G.J.; Onogi H.; Endo Y.; Suzuki S.; Tuchiya A.; Takenoshita S.

Altered expression of E-cadherin in breast cancer: patterns, mechanisms and clinical significance
pp. 90-90(1)
Authors: Asgeirsson K.S.; Jonasson J.G.; Tryggvadottir L.; Olafsdottir K.; Ingvarsson S.; Ogmundsdottir H.M.

Plasminogen activator inhibitor type 2: expression and prognostic value in primary breast cancer
pp. 90-90(1)
Authors: Fersis N.; Ruja A.; Kuo Y.-L.; Friese H.; Thron S.; Bastert G.; Wallwiener D.

Quantitative analysis of circulating tumour cells in breast cancer patients using reverse transcriptase polymerase chain reaction
pp. 90-90(1)
Authors: Wong I.H.N.; Yeo W.; Chan A.T.; Johnson P.J.

Breast cancer: does tumour location influence survival and cosmesis? Experience from 644 patients (1984-1995)
pp. 90-91(2)
Authors: Hammer J.; Track C.; Seewald D.H.; Zoidl J.P.; Labeck W.; Putz E.; Gruy B.

Relationship between insulin-like growth factor 1 (IGF-1), prolactin (PRL), human growth hormone (hGH) and steroid receptors in breast cancer patients
pp. 91-91(1)
Authors: Delgado L.; Alonso O.; Alonso I.; Artagaveytia N.; Alvarez B.; Sabini G.; Roca R.; Muse I.M.

Expression of cyclin dependent kinase inhibitor protein p27kip in localized invasive ductal carcinoma of the breast
pp. 91-91(1)
Authors: Kourea H.; Koutras A.; Zolota V.; Marangos M.; Tzorakoeleutherakis E.; Koukouras D.; Kalofonos H.

Circulating antibodies against a breast tumor antigen
pp. 91-91(1)
Authors: Pasquinelli R.; Capasso I.; D'Aiuto M.; Barba P.; Anzisi A.M.; D'Aiuto G.; Guardiola J.

Correlation between proliferating cell nuclear antigen (PCNA) and p53 protein expression in breast carcinomas. Can they have a prognostic value?
pp. 91-91(1)
Authors: Lazar L.; Berindan I.; Balacescu O.; Risca R.; Neagoe E.; Lazar G.

Increased E-cadherin and keratin 18 expression is associated with better prognosis in patients with human breast cancer
pp. 91-92(2)
Authors: Glienke Y.; Fuchs I.; Buhler H.; Lorenz A.; Opri F.; Voss H.; Schaller G.

Immunohistochemical studies on oncogene products (C-erbB-2) and p53 protein in human breast cancer: is it significant for tumor evolution?
pp. 92-92(1)
Authors: Lazzr L.; Berindan I.; Balacescu O.; Neagoe E.; Risca R.; Lazar G.

Possible causes of breast cancer in women working at coke-chemical factory (CCF)
pp. 92-92(1)
Authors: Gurieva V.A.; Gonopolskaya T.L.; Ivanov E.G.

Determination of fibrin D-dimers in patients with breast cancer after cytotoxic chemotherapy
pp. 92-92(1)
Authors: Koufos C.; Tsavaris N.; Kosmas C.; Travlou A.

Prognostic value of cathepsin D in breast cancer (BC) patients
pp. 92-92(1)
Authors: Adrover E.; Maestro M.L.; Sanz-Casla T.; Del Barco V.; Valor R.

Influence of prognostic factors on overall and disease free survival in male patients with primary carcinoma of the breast
pp. 92-93(2)
Authors: Stranzl H.; Prettenhofer U.; Mayer R.; Quehenberger F.; Willfurth P.; Guss H.; Hackl A.

Male breast cancer - New prognostic factors?
pp. 93-93(1)
Authors: Afonso N.; Pereira D.; Silva C.; Lopes C.

Tomotherapy with peacock: The University of California, Irvine experience
pp. 93-93(1)
Authors: Al-Ghazi M.; Ammirati M.; Kuo J.; Qian Y.; Ramsinghani N.; Yakoob R.

Stereotactic radiotherapy in the treatment of ocular melanoma
pp. 93-93(1)
Authors: Jaywant S.; Michaels H.; Laperriere N.

Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned photon and a standard photon technique
pp. 93-94(2)
Authors: Fuss M.; Hug E.B.; Schaefer R.A.; Nevinny M.; Slater J.D.

Dosimetric imrovements following 3-D planning of tangential breast irradiation
pp. 94-94(1)
Authors: Aref A.; Thornton D.; Youssef E.; He T.; Tekyi-Mensah S.; Denton L.; Ezzell G.

Commissioning and clinical use of a micro multi-leaf collimator for conformal radiosurgery
pp. 94-94(1)
Authors: Schlenger L.; Bohsung J.; Cosgrove V.P.; Groll J.; Jahn U.; Kaiser A.; Pfaender M.; Stuschke M.; Budach V.; Wurm R.E.

A comparative analysis of electronic portal image quality for patients receiving whole pelvic irradiation
pp. 94-94(1)
Authors: Van Den Heuvel F.; Strowbridge A.; Han I.; Chungbin S.; Ragan D.

Impact of new technology on radiation therapy treatment deviations at TSRCC
pp. 94-94(1)
Authors: Robson S.; Pegler R.; Danjoux C.; Chow E.; Franssen E.; Thomas G.

Rectal in-vivo dosimetry in fractionated brachytherapy of cervix cancer with HDR-Fletcher-Applicator (HDR-FA)
pp. 95-95(1)
Authors: Rahim H.; Kametriser G.; Sedlmayer F.; Brandis M.G.; Merz F.; Deutschmann H.; Wurstbauer K.; Kogelnik H.D.

The use of an immobilisation system in the treatment of prostate cancer with conformal radiotherapy - A prospective randomised trial
pp. 95-95(1)
Authors: Nutting C.; Khoo V.; Walker V.; Norman A.; Dearnaley D.P.

Treatment of malignant pericardial effusion with 32P-colloid
pp. 95-95(1)
Authors: Dempke W.; Kegel T.; Voigt W.; Buchele T.; Grothey A.; Schmoll H.J.; Firusian N.

Stereotactic irradiation of uveal melanoma at a 6 MV-linear accelerator - Technical considerations concerning movement verification by video recording
pp. 95-95(1)
Authors: Kren G.; Dieckmann K.; Zehetmayer M.; Bogner J.; Potter R.

Comparison of radiation therapy planning for proton- and photon treatment of pediatric Wilms' tumors
pp. 95-96(2)
Authors: Nevinny M.; Hug E.B.; Fuss M.; Miller D.W.; Lukas P.; Slater J.D.

Photodynamic therapy (PDT) in superficial malignomas using visible light and various photosensitizers plus minus hyperthermia
pp. 96-96(1)
Authors: Kolbabek H.; Jindra R.H.; Kubin A.; Alth G.; Dobrowsky W.

Intensity modulated radiotherapy (IMRT) for carcinoma of the thyroid and parotid gland
pp. 96-96(1)
Authors: Nutting C.; Convery D.; Rowbottom C.; Cosgrove V.; Dearnaley D.P.; Henk J.M.; Harmer C.; Webb S.

Patient diode dosimetry for electron beam treatments: clinical implementation and dosimetric considerations
pp. 96-96(1)
Authors: Yaparpalvi R.; Fontenla D.P.; Vikram B.

Pulsed dose rate brachytherapy in the treatment of head and neck carcinoma
pp. 96-96(1)
Authors: Pokrajac B.; Knocke T.H.; Fellner C.; Seitz W.; Schmid R.; Potter R.

Treatment planning for the second stereotactic radiosurgery utilizing the previous target reconstructed by image fusion
pp. 97-97(1)
Authors: Shibayama C.; Nakazawa M.; Masubuchi J.; Sakai O.; Sugawara T.; Shinoda S.; Hashimoto M.; Masuzawa T.; Furuse M.

'Recumbent position' and Stanford methods of total skin electron irradiation in the treatment of mycosis fungoides: comparison of long-term side effects
pp. 97-97(1)
Authors: Kuten A.; Rosenblatt E.; Bar-Deroma R.; Toffler E.; Cederbaum M.; Stein M.E.

Effectivity of lead blockages of the lung in tangential breast irradiation
pp. 97-97(1)
Authors: Stegmaier P.; Maurer U.; Kaessner J.; Steil V.; Georgi M.

Virtual two dimensional (2D) step wedge for film dosimetry calibration for megavoltage photon beams
pp. 97-97(1)
Author: Meng J.

NSCLC: Dose escalation by target splitting with asymmetric collimation
pp. 97-98(2)
Authors: Wurstbauer K.; Deutschmann H.; Kranzinger M.; Merz F.; Rahim H.; Sedlmayer F.; Kogelnik H.D.

A simple technique for the optimization of the dose distribution in the lower neck and upper thoracic area
pp. 98-98(1)
Authors: Kopp M.; Rahim H.; Deutschmann H.; Kogelnik H.D.

Subcutaneous amifostin during fractionated radiotherapy: a randomized phase II study in pelvic tumours
pp. 98-98(1)
Authors: Koukourakis M.I.; Frangiadaki C.; Stavroulaki A.; Ratalis G.

Total body irradiation (TBI) before bone marrow transplantation (BMT): technique and acute toxicity
pp. 98-98(1)
Authors: Szekely J.; Fabry L.; Forgacs G.; Kontra G.; Petranyi J.; Nemeth G.

External beam radiotherapy of intraocular metastases
pp. 98-98(1)
Authors: Bajcsay A.; Toth J.; Recsan Z.; Kontra G.; Horvath A.; Nemeth G.

Procedures of radiotherapy with boron neutron capture reaction at the Petten irradiation facility
pp. 98-99(2)
Authors: Hideghety K.; Sauerwein W.; Vroegindeweij C.; Moss R.L.; Watkins P.; Garbel S.; Rassow J.

The elekta multileaf collimator (MLC). A universal soldier made to conform
pp. 99-99(1)
Author: Welch M.

HDR boost brachytherapy with flexible implants in breast cancer
pp. 99-99(1)
Authors: Barbera L.; Casas O.; Terrier F.; Giacomi N.; Vigo S.; Pascuale R.; De Angelis C.; Negri H.; Menendez P.

Past, present and future trends of boron neutron capture therapy (BNCT)
pp. 99-99(1)
Authors: Sauerwein W.; Hideghey K.; Moss R.; Busse P.; Harling O.; Zamenhoff R.; Coderre J.; Nakagawa Y.; Pignol J.-P.

Hyperfractionated body stereotactic radiosurgery (BSR)
pp. 99-99(1)
Authors: Qian G.; Lowry J.; Silverman P.; Grosman I.; Lombardi E.; Volpicella F.; Lederman G.

Advanced on-time treatment planning for intraoperative radiotherapy (IORT)
pp. 99-100(2)
Authors: Deutschmann H.; Sedlmayer F.; Kopp M.; Rahim H.; Merz F.; Kopp P.; Hutter J.; Waclawiczek H.W.; Gruber W.; Kogelnik H.D.

Variation in dose distribution for breast radiotherapy: a trial based quality assurance programme in the UK
pp. 100-100(1)
Authors: Deighton A.; Winfield E.A.; Venables K.; Aird E.G.A.; Hoskin P.J.

3D planning for tangential breast irradiation: Feasible and relevant?
pp. 100-100(1)
Authors: Van Gestel D.; Vanregemorter J.; De Ost B.; Vanderkam S.; Meijnders P.; Van den Weyngaert D.

Total body irradiation - Prospective evaluation of early side effects
pp. 100-100(1)
Authors: Obert K.; Mose S.; Jacob-Heutmann D.; Damrau M.; Ramm U.; Rischke H.C.; Fauth F.; Bottcher H.D.

Is the vaginal rod an accurate method to localise the vaginal apex?
pp. 100-100(1)
Authors: Wiggenraad R.; Coerkamp E.; Tamminga R.; Wiersma T.; Sorge A.v.

Intraoperative radiation therapy (IORT) and chemotherapy in treatment of urinary bladder cancer
pp. 101-101(1)
Authors: El-Wahidi G.; Ashamallah A.; Eita M.; Teima S.; Denewer A.; Gomha M.

Preoperative radiotherapy of schistosomal bladder cancer. Prospective randomised study
pp. 101-101(1)
Authors: El-Wahidi G.; Ghoneim M.A.; Saker H.; Fouda M.A.

High-dose-rate brachytherapy after exernal beam irradiation in palliative treatment of squamous cell carcinoma of the esophagus
pp. 101-101(1)
Authors: Eickhoff A.S.; von Lieven H.; Aydin H.; Eickhoff J.C.

Dose optimisation of boost irradiation using electron beam in breast carcinoma
pp. 101-101(1)
Authors: Okutan M.; Kemikler G.; Ozbilen S.; Cakir A.; Aslay I.

Re-evaluation of the study design of the phase I clinical trial with BNCT for patients with glioblastoma at the High Flux Reactor Petten (EORTC protocol 11961)
pp. 101-101(1)
Authors: Hideghety K.; Sauerwein W.; de Vries M.; Wanders J.; Husing J.; Moss R.; Rassow J.; Gabel D.

Comparative study between respiratory gated conventional 2-D plan and 3-D conformal plan for predicting radiation hepatitis
pp. 101-102(2)
Authors: Lee S.W.; Kim G.E.; Chung K.S.; Lee C.G.; Seong J.; Suh C.O.

Measurement of patient entry and exit doses during total body irradiation
pp. 102-102(1)
Authors: Damrau M.; Ramm U.; Manegold K.H.; Mose S.; Rischke H.C.; Jacob-Heutmann D.; Obert K.; Rahl C.G.; Bottcher H.D.

Intraoperative high dose rate interstitial irradiation of hepatic metastases
pp. 102-102(1)
Authors: Villalba S.R.; Ortega M.S.; Mateo A.; Ortega J.; Castell T.; Valderrabamo S.; Lenni A.

The impact a multileaf collimator (MLC) may have on a departments confidence and quality assurance
pp. 102-102(1)
Author: Welch M.

Concurrent radiotherapy and chemotherapy with topotecan and stealth liposomal doxorubicin for the treatment of locally advanced pelvic tumours
pp. 102-102(1)
Authors: Koukourakis M.I.; Chaldeopoulos D.; Lyraraki E.; Varveris C.

Subcutaneous administration of Amifostine in patients treated with radiotherapy. A preliminary report
pp. 102-103(2)
Authors: Ravo V.; Guida C.; Silvestro G.; Spena F.R.; Elmo M.; Pecori B.; Frezza P.

Antiangiogenic and antitumor effect of VEGF antisense oligonucleotide in combination with anti-EGFR C225 monoclonal antibody in human colon cancer
pp. 103-103(1)
Authors: Ciardiello F.; Bianco R.; Damiano V.; Caputo R.; De Placido S.; Fontanini G.; Agrawal S.; Mendelsohn J.; Bianco A.R.; Tortora G.

Free circulating vascular endothelial growth factor (VEGF) is detectable only in small tumours of the WAG/Rij rat rhabdomyosarcoma tumour model
pp. 103-103(1)
Authors: Wynendaele W.; Landuyt W.; van Oosterom A.T.; Lambin P.

Plasma D-dimer levels, serum VEGF, b-FGF and IL-6 in metastatic breast cancer (MBC): correlation with tumour load and response to therapy
pp. 103-103(1)
Authors: Dirix L.; Weytjens R.; Salgado R.; Benoy I.; Vermeulen P.; Prove A.; Van Dam P.; Lemmens J.

In vitro differentiation of endothelial cells (EC) from AC133-positive progenitor cells
pp. 103-104(2)
Authors: Gehling U.M.; Ergun S.; Schuch G.; Schafhausen P.; Kilic N.; Schafer B.; Hossfeld D.K.; Fiedler W.

Genomic instability in bronchial lavage specimens from individuals with no evidence of lung cancer: an early detection marker?
pp. 104-104(1)
Authors: Field J.K.; Liloglou T.; Xinarianos G.; Turnbull L.; Walshaw M.

Tumour cells can eliminate amplified genes
pp. 104-104(1)
Authors: Ambros A.I.; Luegmayr A.; Rumpler S.; Hattinger C.M.; Kovar H.; Gadner H.; Ambros P.F.

Inhibition of NF-kB activation confers sensitivity to TNFa by impairment of cell-cycle progression in human glioma cells
pp. 104-104(1)
Authors: Otsuka G.; Nagaya T.; Saito K.; Mizuno M.; Yoshida J.; Seo H.

Death receptors in etoposide treated lymphoma cells
pp. 104-104(1)
Authors: Mihalik R.; Sebestyen A.; Barna G.; Bauer P.; Kopper L.

'Invading edge vs. inner' vascularisation: angio-genic and angio-preserving activity in non-small cell lung cancer (NSCLC)
pp. 105-105(1)
Authors: Giatromanolaki A.; Koukourakis M.I.; Sivridis E.; O'Byrne K.; Garter K.C.; Harris A.L.

Tumour angiogenesis and response in combined modality treatment of head and neck cancer
pp. 105-105(1)
Authors: Dobrowsky E.; Lang S.; Dobrowsky W.

The importance of timing in thermochemotherapy with tubulin inhibitors
pp. 105-105(1)
Authors: Eikesdal H.P.; Dahl O.

Serum erythropoietin level in anemic cancer patients
pp. 105-105(1)
Authors: Ozguroglu M.; Demir G.; Demirelli F.; Molinas-Mandel N.; Buyukunal E.; Serdengecti S.; Berkarda B.

Selective tumor cell kill by alkyl-lysophospholipids
pp. 106-106(1)
Authors: Zerp S.F.; Ruiter G.A.; Bartelink H.; van Blitterswijk W.J.; Verheij M.

Involvement of cytoskeleton in dynamic adhesion of HT-29 cells to extracellular matrix under flow conditions
pp. 106-106(1)
Authors: Haier J.; Nasralla M.; Nicolson G.L.

Cross-talk between c gamma RIIA and c gamma RIIc on human natural killer cells
pp. 106-106(1)
Authors: Popescu I.; Hirt M.; Calugaru A.; Baiu D.; Manciulea M.; Metes D.; Morel P.; Herberman R.; Sulica A.

Quantification and characterization of micro tumor load: an option for monitoring adjuvant and palliative disease
pp. 106-106(1)
Authors: Habets L.; Grotius O.; Doll S.; Lippok B.; Gajewsky M.; Braun P.; Knechten H.

Analysis of telomerase activity in physiological and pathological endometrial tissues
pp. 106-107(2)
Authors: Jimenez E.; Garcia-Foncillas J.; Guzman M.; Andion E.; Huarriz M.; Okroujnov I.; Errasti T.; Jurado M.; Schneider J.; Brugarolas A.

MUC1 mucin for the detection of epithelial-derived ovarian cancer cells in peripheral blood
pp. 107-107(1)
Authors: Obermair A.; Stimpfl M.; Schmid B.; Tong D.; Schiebel I.; Leodolter S.; Zeillinger R.

Matrix metalloproteinase expression in normal, inflammed and malignant mesothelial tissues
pp. 107-107(1)
Authors: Edwards J.G.; Walker R.A.; McLaren J.; Waller D.A.; Steward W.P.; O'Byrne K.J.

Vascular endothelial growth factor (VEGF) in sera of patients with cervical cancer and the impact of platelets
pp. 107-107(1)
Authors: Hansgen G.; Becker A.; Hintner I.; Dunst J.

Creation of a stage by stage diagnostics system of malignant tumors
pp. 107-107(1)
Authors: Petrov S.; Balatenko N.; Khasanov R.

Genistein inhibits initial dynamic adhesion of HT-29 cells to extracellular matrix under flow conditions
pp. 107-108(2)
Authors: Haier J.; Nasralla M.; Nicolson G.L.

Signal transduccion pathways activated by antineoplasic drugs and their role in apoptosis
pp. 108-108(1)
Authors: Sanchez-Perez I.; Perona R.

Angiogenesis of tumors in childhood. Preliminary study
pp. 108-108(1)
Authors: Moschovi M.; Tsangaris G.T.; Vamvoukakis J.; Anastasiou A.; Van Vliet-Konstantinidou C.; Tzortzatou-Stathopoulou F.

Lymphocyte subpopulations in patients with multiple primary tumors
pp. 108-108(1)
Authors: Robinson E.; Segal R.; Struminger L.; Faraggi D.; El'ad-Yarum R.; Mekori T.

Gain of an intracrine, proliferative loop involving FGF-2 and FGF-receptors in human non-small cell lung cancer (NSCLC) cells
pp. 108-108(1)
Authors: Berger W.; Setinek U.; Elbling L.; Mohr T.; Kindas-Mugge I.; Micksche M.

Effect of the conditioned medium (CM) of bone marrow (BM) fibroblast colony forming units (CFU-F) from patients with solid tumor on the growth of normal CFU-F
pp. 108-109(2)
Authors: Chasseing N.; Honegger A.; Bordenave R.; Hoffer E.; Shanley C.; Rumi L.

Efficient autologous inhibition of tumor growth in a murine model of renal carcinoma
pp. 109-109(1)
Authors: Hugenschmidt H.; Wittig C.; Unger C.; Marme D.; Drevs J.

K+-efflux modulation of cisplatin-induced apoptosis and cytotoxicity to cultured mesothelioma cells
pp. 109-109(1)
Authors: Marklund L.; Henriksson R.; Grankvist K.

In-vivo growth modulation of FaDu-xenografts in nude mice with 2-methoxyoestradiol and oestradiol
pp. 109-109(1)
Authors: Claszen J.; Budach W.; Bamberg M.

p53 protein expression and proliferative activity in renal cell carcinomas
pp. 109-109(1)
Authors: Ioakim-Liossi A.; Pantazopoulos D.; Karakitsos P.; Athanassiadou P.; Stergiou E.; Karkabassi A.; Athanassiades P.; Davaris P.

Differental loss E-cadherin in breast carcinomas
pp. 110-110(1)
Authors: Berindan I.; Balacescu O.; Risca R.; Neagoe E.

The TNF level in plasma and in primary tumor conditional medium in gastric cancer patients
pp. 110-110(1)
Authors: Hipp I.; Volodko N.; Barylka V.; Piddubnyak V.; Bilynsky B.

Apoptotic effects of taxol and radiation on the intestinal kript cells of swiss-albino mice
pp. 110-110(1)
Authors: Ozkan L.; Ozuysal S.; Egeli U.; Balim S.; Tunca B.; Aydemir N.; Cecener G.; Engin K.

Expression on tumors and its metatases of platelet endothelial cell adhesion (PECAM-1), a molecule involvement in transendothelial cell migration and angiogenesis
pp. 110-110(1)
Authors: De La Haba J.; Lucena C.; Munoz E.; Canale M.; Macho A.; Barneto I.; Aranda E.

Fibronectin in cell adhesion. It's expression in breast tumors
pp. 110-111(2)
Authors: Berindan I.; Balacescu O.; Risca R.; Neagoe E.

Dominant properties for the suppression of development of preneoplastic foci in the liver of carcinogen resistant inbred DRH strain rats
pp. 111-111(1)
Authors: Higashi K.; Yan Y.; Denda A.; Konishi Y.

The standards, options and recommendations (SOR) project for the management of childhood cancer
pp. 111-111(1)
Authors: Pinkerton R.; Sommelet D.; Brunat-Mentigny M.; Farsi F.; Martel I.; Philip T.; Ranchere-Vince D.; Thiesse P.

Prognostic value of blasts on day 15 in bone marrow and of molecular evaluation of remission in children with acute lymphoblastic leukemia
pp. 111-111(1)
Authors: Schneider M.; Fasching K.; Stolz F.; Mann G.; Fischer S.; Potschger U.; Gadner H.; Panzer-Grumayer E.R.

Monitoring and functional characterization of rare tumor cells in the haematopoietic system
pp. 111-111(1)
Authors: Mehes G.; Hattinger C.M.; Lorch T.; Luegmayr A.; Gadner H.; Ambros P.F.

Cutaneoes and subcutaneous Ewing's sarcoma - A relatively indolent disease
pp. 111-112(2)
Authors: Chow E.; Merchant T.E.; Pappo A.; Jenkins J.; Kun L.E.

Recommended age for total thyroidectomy in children with MEN-2a syndrome
pp. 112-112(1)
Authors: Kahraman T.; Plukker J.T.M.; Rouwe C.; Tiebosch A.T.M.G.; Hofstra R.; Vermey A.

Second malignant neoplasms (SMNs) in retinoblastoma (RB)
pp. 112-112(1)
Authors: Chuba P.J.; Hamre M.; Blackburn R.; Roarty J.D.; Taub J.W.; Ravindranath Y.; Fontanesi J.

Early prophylactic treatment with high-dose recombinant human erythropoetin (rHuEPO) in children with solid tumors
pp. 112-112(1)
Authors: Zoubek A.; Kronberger M.; Fischmeister G.; Potschger U.; Gadner H.

Results of first multicentric studies of therapy children and adolescents with acute lymphoblastic leukemia in Ukraine
pp. 112-112(1)
Authors: Donska S.; Polischuk R.; Trojanovska O.; Usatchenko V.; Belousova L.; Mischenko I.; Schanina V.; Ivanova I.; Rudko L.; Schevtchenko S.

Incidence of TEL/AML1 fusion genes in children with ALL: risk assessment by BFM and MRD criteria
pp. 113-113(1)
Authors: Fasching K.; Stolz F.; Knig M.; Fischer S.; Mann G.; Haas O.A.; Gadner H.; Panzer-Grmayer E.R.

Ex vivo purging using MC540 photoirradiation therapy enhanced by amifostine (WR 2721)
pp. 113-113(1)
Authors: Danilatou V.; Lydaki E.; Dimitriou H.; Bolonaki I.; Kalmanti M.

Radiotherapy for unresectable or marginally resectable osteosarcoma
pp. 113-113(1)
Authors: Chow E.; Kun L.E.; Merchant T.E.; Kaste S.C.; Pratt C.B.; Shah A.B.

Ewing's sarcoma: a review of treatment outcomes and morbidity in patients aged 16 and less treated in British Columbia between 1980 and 1992
pp. 113-113(1)
Authors: Goddard K.; Wu J.; Fryer C.; Rogers P.; Brown K.

Astrocytomas of the cerebellum in children
pp. 113-114(2)
Authors: Kurtulmaz S.; Serin M.; Akmak A.

Mutations of RB-1 gene in children with leukemia and neuroblastoma
pp. 114-114(1)
Authors: Markakis E.A.; Tsopanomichalou M.; Dimitriou H.; Spandidos D.A.; Stiakaki E.; Kalmanti M.

Ochrobactrum anthropi bacteremia in children with central venous catheters
pp. 114-114(1)
Authors: Stiakaki E.; Bolonaki I.; Maraki S.; Samonis G.; Kambourakis A.; Tselentis I.; Kalmanti M.

Changes of thyroid gland after combined treatment for Hodgkin's disease in children
pp. 114-114(1)
Authors: Parkhomenko R.A.; Shcherbenko O.I.; Snigireva R.Y.; Zelinskaya N.I.; Ardatova G.V.; Nechaeva V.N.

Metastatic brain involvement in children with Ewing's sarcoma
pp. 114-115(2)
Authors: Abramyuk A.; Shparyk Y.

About distribution of primary children's brain tumors in Kazakstan
pp. 115-115(1)
Author: Zhylkaidarova A.

Retinoblastoma in Kazakstan between 1956-1990
pp. 115-115(1)
Authors: Teleuova T.; Mustaphina G.; Volkova M.

Arthroplasty of the knee after resection of a sarcoma in children
pp. 115-115(1)
Authors: Vedzizhev G.M.; Vedzizhev B.G.

3 cases of viral encephalitis in pediatric oncohematologic department in patients at the end of chemotherapy treatment
pp. 115-115(1)
Authors: Bazaluk J.; Ryzhak O.; Derbenjova N.; Galtchinska O.; Donska S.

Acute lymphoblastic leukemia: therapy results in one Pediatric Oncohaematologic Center in Ukraine
pp. 115-115(1)
Authors: Gattchinska O.; Derbenjova N.; Ryzhak O.; Donska S.

Cefepim and ceftazidime in combination with amikacin in febrile neutropenia of childhood: which regimen is more effective?
pp. 115-116(2)
Authors: Berrak S.G.; Canpolat C.; Berik P.

Evaluation of neo-adjuvant chemotherapy for efficacy of retinoblastoma treatment
pp. 116-116(1)
Authors: Kobikov S.; Teleuova T.; Zhylkaidarova A.; Volkova M.; Nurgaliev Z.

Progression markers in serum of patients with multiple myeloma
pp. 116-116(1)
Authors: Sakalova A.; Herbacek I.; Desser L.; Holomanova D.; Mohr T.

CA 15-3 and CA 27-29 serum markers in monitoring breast cancer patients
pp. 116-116(1)
Authors: Lauro S.; Lanzetta G.; Trasatti L.; Bordin F.; Bria E.; Reale M.G.; Frati L.

Effects of navelbine (NVB) on the electrophoretic profile of hyaluronidase (HAase) on Lewis lung carcinoma (LLC)
pp. 116-116(1)
Authors: Voyiatzi S.; Sahpazidou D.; Stravoravdi P.; Papageorgiou A.; Chrysogelou E.; Natsis K.; Toliou T.

Initial levels of the plasma 2 microglobulin in patients with different histological types of non-Hodgkin lymphoma
pp. 117-117(1)
Authors: Filipovic-Ljeskovic I.; Jelic S.; Tomasevic Z.; Milanovic N.

Prognostic subgroups in patients with brain metastases: an analysis of a database containing 1292 patients
pp. 117-117(1)
Authors: Lagerwaard F.J.; Levendag P.C.; Schmitz P.I.M.

Expression of tumor suppressor gene p27 in high grade astrocytomas correlates with survival
pp. 117-117(1)
Authors: Kirla R.; Salminen E.; Haapasalo H.; Talve L.; Kalimo H.

Somatostatin receptor scintigraphy in endocranial tumours and comparative dual isotope study. Tissue characterisation?
pp. 117-117(1)
Authors: Giannakenas C.; Kalofonos H.P.; Apostolopoulos D.; Petsas T.; Kalogeropoulou C.P.; Iliadis H.; Vassilakos P.J.

Phase I clinical trial with BNCT for patients with glioblastoma (EORTC Protocol 11961)
pp. 118-118(1)
Authors: Sauerwein W.; Hideghety K.; Moss R.; Goetz C.; Pacquis P.; Rassow J.; Grochulla F.; Haselsberger K.; Wolbers J.; Turowski B.; Fankhauser H.; Stecher-Rasmussen F.; de Vries M.; Gabel D.

Enhanced expression of drug-resistance protein LRP in astrocytic brain tumor cells
pp. 118-118(1)
Authors: Spiegl-Kreinecker S.; Buchroithner J.; Fischer J.; Micksche M.; Berger W.

Supratentorial low-grade glioma: results and prognostic factors following postoperative radiotherapy
pp. 118-118(1)
Authors: Grabenbauer G.G.; Roedel C.M.; Paulus W.; Fahlbusch R.; Sauer R.

A brain cancer clinical assessment tool (BC CAT) for monitoring disease status in high-grade gliomas
pp. 118-118(1)
Authors: Osoba D.; Zee B.; Brada M.; Yung W.K.A.; Weng C.S.W.; MacDonald D.

Comparison of radiotherapy dose distribution and FDG-PET after irradiation in patients with malignant glioma
pp. 118-119(2)
Authors: Paulsen F.; Muller-Berg M.; Becker G.; Reimold M.; Hipp P.; Hehr T.; Buchgeister M.; Muller-Schauenburg W.; Bares R.; Bamberg M.

Establishment of a nitrosourea-resistant in vivo brain-tumor model: for evaluation of different appraoches to conquer the resistance
pp. 119-119(1)
Authors: Manome Y.; Watanabe M.; Kunieda T.; Ohno T.

Hypermethylation of the hMLH1 promoter region in high-grade gliomas
pp. 119-119(1)
Authors: Andion E.; Garcia-Foncillas J.; Salgado E.; Jimenez E.; Huarriz M.; Guzman M.; Okroujnov I.; Vanaclocha V.; Villares G.; Brugarolas A.

Linear accelerator based stereotactic radiosurgery (SRS) as an initial treatment for brain metastases: we can control the tumors 2 cm or less with SRS alone
pp. 119-119(1)
Authors: Hayashi N.; Uchida T.; Okimoto T.; Minami K.; Hayashida M.; Morikawa M.; Ochi M.; Hayashi K.; Shibata S.; Honda S.

Increased expression of heterodisperse Alu-containing transcripts in glioblastoma multiforme
pp. 119-119(1)
Authors: Kavsan V.; Dmitrenko V.; Shostak K.; Garifulin O.; Homenko O.; Zozulya Y.

Intraoperative radiotherapy (IORT) for high grade glioma of the brain - Treatment planning, dose verification, and results
pp. 120-120(1)
Authors: Schueller P.; Ruebe C.; Palkovic S.; Prott F.-J.; Wagner W.; Willich N.

High-dose chemotherapy (HDCT) with G-CSF support before radiotherapy (RT) in malignant gliomas (MG): phase II trial
pp. 120-120(1)
Authors: Vinolas N.; Gil M.; Verger E.; Villa S.; Pujol T.; Caral L.; Garcia M.; Graus F.; Estape J.

Treatment of glioblastoma multiforme (GBM) with teniposide (VM26) and Iomustine (CCNU) followed by radiotherapy
pp. 120-120(1)
Authors: Mane J.M.; Barcelo J.R.; Rubio I.; Fernandez R.; Fuente N.; Abon G.; Munoz A.; Lopez-Vivanco G.

Radiotherapy in primary spinal cord astrocytoma
pp. 120-120(1)
Authors: Ozyigit G.; Zorlu F.; Gurkaynak M.; Cengiz M.; Atahan I.L.

Stereotactic radiotherapy for solitary brain metastases as alternative to surgery
pp. 120-121(2)
Authors: Kaiser A.; Bohmer D.; Fitzek M.; Koerner M.; Matnjani G.; Rosche L.; Stotzer U.; Stuschke M.; Budach V.; Wurm R.E.

Biological evaluation on short course conformal radiotherapy of malignant gliomas
pp. 121-121(1)
Authors: Mangel L.C.; Kiss T.; Horvath A.; Skriba Z.; Somogyi A.; Nemeth G.

Preliminary results of a phase II study: irinotecan (CPT 11) in chemotherapy naive patients with glioblastoma
pp. 121-121(1)
Authors: Fabbro M.; Frenay M.; Raymond E.; Rodier J.M.; Boige V.; Jourdan R.; Risse M.L.; Armand J.P.

Combined therapy of PNET/medulloblastoma in children and young adults - Single institution expirience
pp. 121-121(1)
Authors: Golubicic I.; Nikitovic M.; Bokun J.; Radosevic-Jelic L.

Continuous hyperfractionated accelerated radiation therapy (chart) with fotemustine for malignant gliomas
pp. 121-121(1)
Authors: Yaman F.; Altun M.; Altin S.; Tenekeci A.; Bavbek E.; Onat H.

Effect of tiazofurin on cell cycle and apoptosis induction on C6 rat glioma cells
pp. 122-122(1)
Authors: Vracar M.; Piperski V.; Jokanovic M.; Jovic V.; Rakic L.

A 30-year trek through the arcanes of clinical research
pp. 123-123(1)
Author: Horiot J.-C.

The genetic profile of marginal zone B-cell lymphoma
pp. 123-124(2)
Authors: Dierlamm J.; Wlodarska L.; Baens M.; Stefanova M.; Hinz K.; Stul M.; Michaux L.; Verhoef G.; Thomas J.; Hossfeld D.K.; Hagemeijer A.; De Wolf-Peeters C.; Marynen P.; Van den Berghe H.

The causes of cancer
pp. 125-125(1)
Author: Peto R.

Early breast cancer - the randomised evidence
pp. 126-126(1)
Authors: Peto R.; Clarke M.; Collins R.; Davies C.; Godwin J.; Gray R.

Improving outlook for ovarian cancer - fact or fiction?
pp. 126-126(1)
Author: Kaye S.B.

Adjuvant and palliative therapy for colorectal cancer
pp. 126-126(1)
Author: Glimelius B.

Palliative treatments for metastatic cancer, and use of quality of life endpoints to assess them
pp. 126-127(2)
Author: Tannock I.F.

Conflict of interest
pp. 127-127(1)
Author: Holmberg L.

Collaboration between large intergroups and the pharmaceutical industry
pp. 127-127(1)
Author: Piccart M.J.

The coordinating role of the EORTC
pp. 127-127(1)
Author: Francoise M.

The view from the pharmaceutical industry
pp. 127-127(1)
Author: Blackledge G.R.P.

Antigens recognized by T lymphocytes on kidney cancer
pp. 128-128(1)
Authors: Van den Eynde B.J.; Probst-Kepper M.; Boon T.

Dendritic and tumour cell -derived exosomes as novel cancer vaccines
pp. 128-128(1)
Authors: Zitvogel L.; Lozier A.; Wolfers J.; Regnault A.; Masurier C.; Fernandez N.; Raposo G.; Amigorena S.

T-cell immunity against tumors, a delicate balancing act involving dendritic cells
pp. 128-128(1)
Author: Melief C.

Vaccination with gene-modified tumor cells
pp. 128-128(1)
Author: Parmiani G.

Important issues in palliative oncology
pp. 128-129(2)
Author: Maher E.J.

Pain control for bone metastases
pp. 129-129(1)
Authors: Leer J.W.H.; Steenland E.; van Houwelingen H.

Radiation treatment for bone metastases from prostrate cancer
pp. 129-129(1)
Author: Russell M.

Brain metastases - Radiosurgery or whole brain irradiation?
pp. 129-129(1)
Authors: Wurm R.E.; Schlenger L.; Kaiser A.; Komer M.; Fitzek M.; Roschel L.; Bohmer D.; Matnjani G.; Stuschke M.; Budach V.

Retreatment in head and neck squamous cell carcinoma
pp. 129-130(2)
Authors: Bourhis J.; DeCrevoisier R.; Eschwege F.

The estrogen receptor as a target for breast cancer prevention
pp. 130-130(1)
Author: Jordan C.V.

Coactivators and hormone action
pp. 130-130(1)
Authors: White R.; Mak H.Y.; Heery D.M.; Kalkhoven E.; Valentine J.; Bevan C.; Parker M.G.

Er - New development
pp. 130-130(1)
Author: Gustafsson J.-.

Genetic dissection of glucocorticoid receptor function in mice
pp. 130-130(1)
Author: Schutz G.

New antioestrogens for breast cancer
pp. 130-130(1)
Author: Howell A.

How to respond to complementary medicine: introduction
pp. 130-130(1)
Author: Smyth J.F.

The complementary medicine: the promotors, the prescriptors and the users in different countries
pp. 131-131(1)
Author: Schraub S.

The use of complementary medicine in the German speaking countries
pp. 131-131(1)
Author: Jungi W.F.

Why do people affected by cancer use complementary therapies and how can their efficacy be evaluated?
pp. 131-131(1)
Author: Wilkinson S.

Oncology nurses' attitudes towards alternative medicine
pp. 131-131(1)
Author: Salmenpera L.

The interaction of patient selection, surgical expertise and intensive care competence in esophageal cancer
pp. 131-132(2)
Author: Lerut T.

Quality of surgery and outcome in gastric cancer surgery
pp. 132-132(1)
Authors: Beger H.G.; Schwarz A.

Liver tumor surgery: quality of surgery and outcome on the basis of a large interdisciplinary treatment unit
pp. 132-132(1)
Author: Bismuth H.

Surgical oncology - The volume-outcome impact. Breast cancer
pp. 132-132(1)
Author: Sainsbury R.

Eps8 and E3b1 mediate transduction of signals from Ras to Rac
pp. 132-132(1)
Authors: Scita G.; Tenca P.; Panunzio M.; Betsholtz C.; Di Fiore P.P.

In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery
pp. 133-133(1)
Author: Lacal J.C.

The role of the c-erGB-4/HER4 receptor in cancer
pp. 133-133(1)
Author: Gullick W.

HER2/neu oncoprotein of human adenocarcinomas: an amplifier of signal transduction by stromal growth factor
pp. 133-133(1)
Author: Yarden Y.

Oncogenic signalling through small GTPases
pp. 133-133(1)
Author: Marshall C.J.

Speaker against: are we ready to use tamoxifen to prevent breast cancer in daily practice?
pp. 134-134(1)
Author: Powles T.J.

MDR - Proteins and their clinical relevance
pp. 135-135(1)
Authors: Pinedo H.M.; Lankelma J.; Jansen G.; Broxterman H.J.

Can we predict the efficacy and side effect of radiotherapy
pp. 135-135(1)
Author: Overgaard J.

What constitutes quality in breast cancer surgery
pp. 135-135(1)
Author: Rutgers E.J.T.

Is age a prognostic factor?
pp. 135-136(2)
Author: Mott M.G.

Computer-aided oncology: from basic research to clinical practice
pp. 136-136(1)
Author: Sgouros J.

Knock-out mice in cancer research
pp. 136-136(1)
Authors: Berns A.; Vooijs M.; Marino S.; Jonkers J.; Meuwissen R.; Vink J.; Van der Gulden H.; Krimpenfort P.

Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer
pp. 137-137(1)
Authors: Ross P.; Cunningham D.; Scarffe H.; Nicolson M.; Seymour M.; Harper P.; Price T.; Hill A.; Anderson H.; Iveson T.; Hickish T.; Lofts F.; Norman A.

Efficacy of 5FU + cisplatin (FUP) compared to bolus 5FU (FU) in advanced pancreatic carcinoma (APC)
pp. 137-137(1)
Authors: Ducreux M.; Douillard J.Y.; Pignon J.P.; Seitz J.F.; Bugat R.; Bosset J.F.; Merrouche Y.; Raoul J.L.; Ychou M.; Rougier P.

Locally advanced pancreatic carcinoma: neoadjuvant radiochemotherapy (RCT) with 5-fu and Mitomycin C
pp. 137-137(1)
Authors: Brunner T.B.; Grabenbauer G.G.; Kastl S.; Hohenberger W.; Sauer R.

High incidence of K-Ras mutations in the bile fluids of patients with primary sclerosing cholangitis
pp. 137-138(2)
Authors: Kubicka S.; Meier P.; Flemming P.; Kumhnel F.; Rudolph K.; Manns M.P.

A randomized trial on hepatic arterial CDDP and i.v. 5-FU in unresectable colorectal liver metastases
pp. 138-138(1)
Authors: Cosimelli M.; Tedesco M.; Mancini R.; Giannarelli D.; Garufi C.; Tipaldi L.; Cortesi E.; Di Tora P.; Capussotti L.

Basal level gene expression of thymidylate synthase (TS) in colorectal cancer and normal colon mucosa - No evidence of relation to disease course
pp. 138-138(1)
Authors: Larsson P.-A.; Odin E.; Wettergren Y.; Larsson L.; Carlsson G.; Gustavsson B.

Value of peptide receptor imaging using indium-111-octreotide (OCT) and iodine-123 vasoactive intestinal peptide (VIP) in patients with carcinoid tumours: Vienna University experience 1993-1998
pp. 138-138(1)
Authors: Raderer M.; Kurtaran A.; Niederle B.; Vorbeck F.; Vierhapper H.; Scheithauer W.; Angelberger P.; Pidlich J.; Virgolini I.

Health-related quality of life in five-year survivors of endocrine gastrointestinal tumours
pp. 138-139(2)
Authors: Larsson G.; Sjoden P.O.; Oberg K.; von Essen L.

Advanced esophageal cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil and cisplatin (HLFP regimen)
pp. 139-139(1)
Authors: Taieb J.; Artru P.; Louvet C.; Mabro M.; Carola E.; Lucchi E.; Krulik M.; de Gramont A.

Tobacco, alcohol and the risk of stomach cancer in Canada
pp. 139-139(1)
Authors: Hu J.; Mao Y.; Ugnat A.-M.

5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC)
pp. 139-139(1)
Authors: Roth A.D.; Maibach R.; Fazio N.; Pagani O.; Morant R.; Stupp R.; De Braud F.; Sessa C.; Borner M.M.; Herrmann R.; Goldhirsch A.

Eight-hour infusion versus bolus injection of doxorubicin in EAP regimen in patients with advanced gastric cancer (AGC): a prospective randomised trial
pp. 139-139(1)
Authors: Popov I.; Jelic S.; Radosavljevic D.; Nikolic-Tomasevic Z.

Randomized trial of preoperative (PRT) and intraoperative (IORT) radiotherapy versus surgery alone in resectable gastric cancer
pp. 139-140(2)
Authors: Skoropad V.; Berdov B.

Clinical study on intraperitoneal hyperthermic perfusion chemotherapy for patients with gastric cancer
pp. 140-140(1)
Authors: Cao X.F.; Wu W.M.; Qiu H.Y.; Wu B.C.; Cai M.H.; Za W.Z.

Evaluation for multiple cancer in cases of endoscopic mucosal resection for early gastric carcinoma
pp. 140-140(1)
Authors: Suzuki T.; Nakamura T.; Matsu-ura A.; Yamao K.; Ohashi K.

Expression of thymidylate synthase and its prognostic value in gastric carcinoma with adjuvant 5-fluorouracil containing chemotherapy
pp. 140-140(1)
Authors: Lim H.Y.; Choi J.H.; Kim H.S.; Nam D.K.; Kim H.C.; Joo H.J.

Effects of high dose-rate intraluminal brachytherapy (HDR-ILBRT) for the patients with esophageal squamous cell carcinoma (SCC)
pp. 140-140(1)
Authors: Iwasa M.; Iwasa Y.; Ohmori Y.; Kume M.; Ogoshi S.; Ogawa Y.; Yoshida S.

Effect of T and N stages on outcome of chemoradiation for carcinoma of anus
pp. 140-141(2)
Authors: Ngan S.; Smith J.; Chao M.; Lim-Joon D.

A phase II study of hypofractionated radiotherapy in combination with Gemcitabin in the palliative treatment of advanced pancreatic carcinoma
pp. 141-141(1)
Authors: Antonisse I.E.; van Groeningen C.J.; Langendijk J.A.; Slotman B.J.

Phase I/II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer
pp. 141-141(1)
Authors: Yamao T.; Maruyama M.; Shirao K.; Matsumura Y.; Yamada Y.; Muro K.; Sugano K.; Shimada Y.

Stage-adapted radio-chemotherapy in anal canal carcinoma
pp. 141-141(1)
Authors: Landmann C.; Amsler B.

Hepatocellular carcinoma: adjuvant chemotherapy postliver transplant
pp. 141-142(2)
Authors: Villanueva M.J.; Navarro F.; Sanchez A.; Provencio M.; Bonilla F.; Cuervas-Mons V.; Espana P.

Localised squamous - cell cancer of the oesophagus: retrospective analyzis of three results
pp. 142-142(1)
Authors: Delcambre C.; Jacob J.H.; Segol P.; Ollivier J.M.; Gignoux M.; Pottier D.; Vie B.; Roussel A.

Radio-chemotherapy and high dose rate (HDR) brachytherapy in the treatment of esophageal cancer
pp. 142-142(1)
Authors: von Briel C.; Borner M.; Greiner R.H.

The royal marsden experience with chemo-radiation using protracted infusional (PVI) 5-fu and cisplatin with conformal radiotherapy (CR-RT) in locally advanced oesophageal cancer
pp. 142-142(1)
Authors: Tait D.; Walters J.; Norman A.; Ross P.; Cunningham D.

First line treatment with docetaxel (D) and gemcitabine (G) in patients with inoperable pancreatic cancer: a multicenter phase II study
pp. 142-143(2)
Authors: Androulakis N.; Stathopoulos G.; Tsavaris N.; Aravandinos G.; Samantas E.; Papakostas P.; Kouroussis C.; Fountzilas G.; Kakolyris S.; Mavroudis D.

Direct endoscopic injection of cisplatin/adrenaline gel for palliation of dysphagia in patients with advanced esophageal cancer
pp. 143-143(1)
Authors: Harbord M.; Viens P.; Eysselein V.; Barr H.; Bown S.G.

Radiochemotherapy in anal canal carcinoma (ACC). A randomized clinical trial comparing FluoroUracil-Cisplatinum (5FU-CDDP) and CDDP alone
pp. 143-143(1)
Authors: Gerard J.P.; Romestaing P.; Mornex F.; Ardiet J.M.

Complete peritonectomy associated with intra peritoneal hyperthermic perfusion in the treatment of Pseudomyxoma Peritonei: experience at the National Cancer Institute of Milan
pp. 143-143(1)
Authors: Deraco M.; Santoro N.; Inglese M.G.; Guadagni S.; Maucione A.; Azzarelli A.; Mazzaferro V.; Zanna M.; Vaglini M.

Concurrent high dose radiotherapy and cisplatinum-based chemotherapy +/- immunotherapy versus radiotherapy alone in esophageal carcinoma. Molecular biology in assesment of response to chemoradiotherapy
pp. 143-144(2)
Authors: Ibrahim S.M.; Ali A.K.; Faraag A.A.; Hamed S.E.; Abdel Hafeez Z.M.

Prognostic value of tumor suppressor gene (P53) and multiple drug resistance transport protein (P170) in hepatocellular carcinoma (HCC)
pp. 144-144(1)
Authors: Saber M.; Atef H.; Mansour M.; Youssry A.; Abdel-Ghany M.S.; El-Derini S.

3D-conformal radiotherapy (3D-CRT) for pancreatic cancer: acute toxicity and quality of life in the experience of the European Institute of Oncology
pp. 144-144(1)
Authors: Gatti G.M.; Castiglioni S.; Ghilezan M.; Ivaldi G.B.; Catalano G.; Leonardi M.C.; Greco C.; Vavassori A.; Marsiglia H.; Orecchia R.

A randomised trial of brachytherapy before (BRYB) and after (BRYA) external beam irradiation (XRT) for carcinomas of the oesophagus and cardia
pp. 144-144(1)
Authors: Haylock B.J.; Hay J.H.; Flores A.D.; Evans K.D.; Nelems B.; Finley R.J.

Phase II study of docetaxel (D) as salvage chemotherapy in patients with advanced gastric cancer
pp. 145-145(1)
Authors: Vanhoefer U.; Harstrick A.; Wilke H.; Achterrath W.; Preusser P.; Stahl M.; Fink U.; Seeber S.

Transhiatal oesophagectomy in the treatment of carcinoma of the lower oesophagus and cardia of the stomach - influence of preoperative risk factors
pp. 145-145(1)
Authors: Loukanov T.; Dimitrov V.; Djongov L.

3-Dimensional planned conformal radiation technique (3D-RT) compared to standard 2 isocentric fields AP-PA radiation technique (APPA-RT) in anal cancer
pp. 145-145(1)
Authors: Gerber E.; Cerveny M.; Krausz H.; Baur M.; Karner J.; Sellner F.; Wunderlich M.; Tuchmann A.; Hold M.; Schratter-Sehn A.

Whole body hyperthermia (WHB, 41.8^oC) in combination with chemotherapy in gastrointestinal (GI) cancer
pp. 145-145(1)
Authors: Panse J.; Nierhaus A.; Meissner-Kuck C.; Hegewisch-Becker S.; Hossfeld D.K.

The role of different preoperative treatment modality in esophageal carcinoma management
pp. 145-146(2)
Authors: Ganul V.; Bondarouk O.; Kirkilevsky S.; Pidlubna T.; Zajtcev S.

Concurrent chemoradiotherapy using low-dose continuous infusion of 5-fluorouracil for stage 2-3 esophageal cancer: a 3-year follow-up report
pp. 146-146(1)
Authors: Sakai K.; Sugita T.; Tsuchida E.; Matsumoto Y.; Sasamoto R.

Intra-arterial chemotherapy (iaCT) combined with radiation (RT) for advanced pancreatic cancer
pp. 146-146(1)
Authors: Osinsky D.; Yugrinov O.; Chorny V.; Rozumej D.

Combination therapy with Oxaliplatin + Gemcitabine in advanced pancreatic cancer
pp. 146-146(1)
Authors: Klapdor R.; Martini-Svendsen J.; Seutter R.; Fenner C.

Local effect of cisplatin/epinephrine injectable gel on intrahepatic lesions of hepatocellular carcinoma (HCC)
pp. 146-146(1)
Authors: Yu S.C.H.; Leung T.W.T.; Lau W.Y.; Chan Y.L.; Tang A.M.Y.; Metreweli C.; Johnson P.J.